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The thesis work presented here focuses on AKAP18γ mediated multivalent 
complex formation and its oligomerization. AKAP18γ belongs to a family of structurally 
diverse but functionally analogous scaffolding proteins called A-Kinase Anchoring 
Proteins (AKAPs). These scaffolds specifically target Protein Kinase A (PKA) 
holoenzyme to a distinct cellular compartment to regulate PKA activity and substrate 
specificity. Previously, the long isoforms of an AKAP called AKAP18 (AKAP18γ/δ) 
were established as important cardiac calcium regulating proteins due to their ability to 
mediate phosphorylation of a protein called Phospholamban (PLN). My dissertation work 
shows that AKAP18γ directly interacts with Inhibitior-1 (I-1) and enhances its 
phosphorylation under stimulatory conditions. The AKAP18γ-PKA-I-1 complex together 
regulates Protein Phosphatase 1 (PP1), also found to be associated with this complex. 
PP1 is a negative regulator of cardiac function due to its ability to dephosphorylate PLN. 
Based on these results, we propose a model in which AKAP18γ acts as multivalent 
complex organizing scaffold that may be targeted to the sarcoplasmic reticulum in 
cardiac myocytes for PLN phosphorylation regulation.  This complex may be found in 
other cell types to regulate PP1 function alone as I-1, PP1 and AKAP18γ have been 
found in other tissue. 
  
Arpita Singh- University of Connecticut, 2013 
 
Moreover, I also discovered that AKAP18γ is an oligomerizing scaffold and the 
interaction is isoform specific. A shorter isoform of this gene, AKAP18α does not 
oligomerize and there is no hetero oligomerization between these isoforms (AKA18α and 
AKAP18γ). Live cell microscopy shows that AKAP18γ can form heterogenous 
oligomers ranging from monomers to tetramers in cells. Furthermore, in order to 
understand the physiological implication of this oligomerization, we developed a 
computational model. The model was based on activation and release of PKA catalytic 
subunit, which requires PKA regulatory subunit phosphorylation. Presence of multiple 
PKA holoezymes will potentiate release of multiple PKA catalytic subunits due to 
increased PKA regulatory subunit phosphorylation. When this possibility was tested 
against a generic membrane compartmentalized substrate, the computational model 
revealed increased PKA mediated phosphorylation of the substrate. These results are 
suggestive of a mechanism in which AKAP18γ oligomerizes to mediate enhanced 
substrate phosphorylation by PKA.  
Based on the evidence presented in this thesis and work done by others, it appears 
that AKAP18γ not only regulates PLN phosphorylation but also its de-phosphorylation 
by regulating PP1 activity. Importantly, AKAP18γ can oligomerize which may be the 
potential mechanism by which AKAP18γ concentrates enzymes required for PLN 
regulation. The title of the thesis “AKAP18: bidirectional regulator of protein 
phosphorylation” reflects these properties of AKAP18γ. 
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1. INTRODUCTION 
 
1.1.  SCAFFOLDING PROTEINS IN CELL FUNCTION 
  The last two decades have been crucial in advancing our understanding of cellular 
signaling. The vaguely understood mechanisms by which cells relay specific signals 
inside the cytoplasm are now becoming clearer. One of the key drivers of this research 
has been the discovery of scaffolding proteins (1-3). These intracellular proteins form 
connections to transmit information from one signal point to the next by organizing 
signaling complexes that consist of specific proteins. This is important to ensure signal 
relay to precise proteins at the right time. Diffusion of molecules in the cytoplasm 
opposes this phenomenon due to randomness inherent to diffusing systems. To get 
around this problem, cells have evolved mechanisms to immobilize signaling proteins. 
Signaling proteins can be co-localized by a few mechanisms. As shown in figure 1, the 
three major ways of doing this involves:  co-localization of proteins to a specific cellular 
location, organelle formation and assembly of multi-molecular complexes by tethering 
proteins to cellular scaffolds (4). 
Structurally, scaffolds are diverse proteins and their molecular architecture 
depends on the pathway they regulate. Even though the structures and origins of these 
proteins are diverse, they have a common converging function of signal integration, 
propagation and sometimes, termination. Since there is no strict definition of a 
scaffolding protein that is used by the scientific community, proteins can be defined as 
scaffolding proteins based on their functional properties. The four most important  
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Figure 1.1: Representative image showing mechanisms of distinct signaling 
compartment formation in cells.  
Shown on left is a cell without signaling compartments. The hypothetical signaling 
pathway involves the yellow, light green and blue molecules represented as circles. In 
grey are the other nonspecific molecules in the cell. Shown on right, is a cell with specific 
signaling compartments. These compartments or micro-domains are structured in a cell 
by localizing specific proteins at a specific location in the cell. In this case, the yellow, 
light green and blue signaling molecules involved in a hypothetical signaling pathway 
can be compartmentalized by co-localization, by organelle formation or by binding to a 
scaffolding protein.  
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functions of a scaffold can be delineated as: 1) they act as molecular platforms for 
assembly of signaling molecules, 2) they localize signaling molecules at a distinct 
cellular location, 3) they coordinate negative and positive feedback signals to regulate 
signaling pathways and 4) they protect activated signaling molecules from getting 
inactivated.  Most scaffolds will have at least two of the above described properties (5).  
Sometimes, the scaffolds may themselves be subjected to different alterations, such 
as phosphorylations, sumoylations, and acetylations, to improve their efficiency of signal 
regulation. A well-understood example is phosphorylation of LAT (Linker for Activated 
T cells) and SLP-76 (Leukocyte Specific Phosphoprotein) scaffold by a tyrosine kinase 
Zap70 for T cell activation. The multiple phosphorylations of these scaffolds enable them 
to interact with several Src Homology 2 (SH2) domain containing proteins leading to 
activation of major signaling pathways involved in T cell activation (6, 7). Scaffolds are 
also capable of interacting with other scaffolding proteins to augment signal transmission, 
especially from one pathway to another. For example, a recent study showed that RACK1 
(Receptor for Activated C Kinase), a PKC (Protein Kinase C) scaffold interacts with 14-
3-3ζ (8). The interaction between these two scaffolding proteins enables translocation of 
RACK1 into the nucleus to activate expression of a transcription factor (8).   
Another important mechanism that scaffolds may use to improve function is self-
interaction, forming oligomers.  The JNK (c-Jun N-terminal Kinase) associated scaffold 
WDR62 (W-tryptophan D-aspartic acid Repeat domain 62) involved in mitosis 
regulation, dimerizes using a C-terminus motif downstream of the JNK binding site. 
WDR62 mutants incapable of dimerization cannot efficiently bind JNK hence affecting 
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the signaling pathway (9). The C4b-binding protein is a heptameric scaffold found in 
immune cells for inhibiting the classical complement pathway and the lectin pathway 
(10). Heptamer formation by C4b- binding protein increases its half-life in blood serum 
and helps it tether and circulate the anti blood coagulating S-protein in mammals. The 
extra-ordinary stability of this heptameric scaffold protein has made it an ideal candidate 
for drug delivery (11). Overall, scaffolds are recognized as important proteins that assist 
in maintaining fidelity and efficiency of signal transduction pathways in a cell.  
 
1.2.  AKAPS AND THEIR ROLE IN PKA SIGNAL INTEGRATION AND 
REGULATION 
 One of the most characterized second messenger pathways involves cAMP 
signaling (shown in figure 1.2).  For the heart, binding of norephinephrine to β-
adrenergic (β-AR) receptors found on the cell membrane results in the activation of a 
small G-protein termed Gαs (12).  Once active, the Gαs protein binds to the enzyme 
adenylyl cyclase (AC), thereby stimulating the production of cAMP (13).  The major 
target of cAMP is the cAMP-dependent protein kinase A (PKA) (14). The PKA 
holoenzyme consists of two regulatory and two catalytic subunits (15, 16). Each 
regulatory subunit binds a single catalytic subunit. This gives rise to a tetrameric PKA 
holoenzyme (17, 18). Activation of PKA occurs when 2 molecules of cAMP bind to each 
of the regulatory subunits, resulting in dissociation of the catalytic  
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Figure 1.2: Diagram showing activation of cAMP inside a cardiac myocyte. 
cAMP activation in the cell requires activation of β-adrenergic receptors (represented as 
β-AR) upon binding of norepinephrine. This causes conformational changes in this ligand 
receptor leading to disassociation of the Gαs protein from the β-AR receptor protein 
bound trimeric G-protein complex intracellularly. Gαs traslocates to bind and activate the 
proximally localized adenylyl cyclases enzyme (represented as AC). Activated AC 
conducts breakdown of ATP to produce cAMP in the cell. The red to yellow gradient 
shown in the figure represents a cellular microdomain in which the cAMP production is 
localized. Specific cAMP microdomain formation is dependent on the ligand that leads to 
activation of AC in the cell. It has been found that different ligands give rise to different 
cAMP micro-domains for regulation of specific intra-cellular signaling proteins.  
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subunit (shown in figure 1.3).  The now active catalytic subunit is free to phosphorylate 
target substrates. Inactivation of PKA occurs by hydrolysis of cAMP by enzymes called 
as Phosphodiesterases (PDEs) (19). Reduction of cAMP in cellular environment causes 
reassociation of PKA regulatory and catalytic subunit and hence PKA enzyme 
inactivation (20).  
Mammals express 4 types of regulatory subunits, RIα, RIβ, RIIα, and RIIβ and 3 
types of catalytic subunits (Cα, Cβ, Cγ) (21).  All the isoforms of the catalytic subunit 
can interact with any of regulatory homodimers giving rise to various combinations. A 
PKA tetramer consisting of R1 (α or β) regulatory dimer is called as Type 1 PKA 
holoenzyme, whereas a PKA tetramer consisting of RII (α or β) regulatory dimer is 
called as Type II PKA holoenzyme (22). The tissue expression of these proteins is 
tightly regulated in order to achieve PKA function specificity (23).   
Scaffolding proteins involved in regulation of Protein Kinase A (PKA) mediated 
phosphorylation are called as A-Kinase Anchoring Proteins (AKAPs).  These scaffolds 
regulate the specificity and rapidity of substrate phosphorylation by tethering both the 
PKA holoenzyme and its cellular target to a specific subcellular domain (21, 24).  
AKAPs demonstrate three distinct properties to regulate substrate specificity (shown in 
figure 1.4); they must bind the holoenzyme of PKA, direct the kinase to a specific 
subcellular domain, and integrate multiple signaling enzymes that may be required for the 
regulation of the same or distinct signaling pathways.  These properties are discussed in 
detail below (25).  
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Figure 1.3: Activation and deactivation  of PKA catalysis. 
Representative diagram shows the sequence of events involved in PKA holoenzyme 
activity regulation. PKA tetramer, also called as PKA holoenzyme consists of two 
regulatory subunits (shown as yellow triangles) that can dimerize. Each monomer of the 
regulatory dimer can bind to a single catalytic subunit, giving rise to the PKA tetramer 
(holoenzyme). The binding of the PKA catalytic subunit to the regulatory subunit keeps 
the catalytic subunit inactive. In order to activate the PKA catalytic subunit, cAMP is 
required. Under conditions of high cAMP, each regulatory subunit binds to two cAMP 
molecules (green circles). Binding of cAMP to the regulatory subunit causes release of 
catalytic subunit, which is free to catalyze phosphorylation of a Substrate (shown in 
mauve) using an ATP molecule. PKA catalytic subunit is deactivated by hydrolysis of 
cAMP by PDE. Loss of PKA regulatory subunit cAMP binding, promotes reassociation 
of PKA regulatory and catalytic subunits leading to reformation of the PKA holoenzyme 
and termination of PKA catalysis.  
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Figure 1.4:  Representative image of an AKAP showing its properties and functions.  
Three defining properties of an AKAP (in green): 1) Binds to the PKA holoenenzyme via 
the Regulatory subunit (shown in yellow) to localize Catalytic subunit (shown in red), 2) 
gets targeted to a specific cellular compartment (shown here an AKAP targeted to a 
membranous compartment), and 3) interacts with other proteins which might be involved 
in the signaling pathway (A and B proteins). Substrate phosphorylation can occur in 3 
ways. Shown here are: Substrate 1 that is membrane associated and directly interacts with 
the AKAP for localization; Substrate 2 is bound to the AKAP directly and Substrate 3 
present in the membrane but does not contribute to the targeting of the AKAP. Other 
AKAPs can get localized to a membrane via protein-protein interaction alone without 
interacting with the membrane (not shown here). 
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To be considered an AKAP, the scaffold must first bind PKA (26).  This occurs 
via an amphipathic helix on the AKAP consisting of 14-18 amino acids that binds by 
hydrophobic interactions to the N-terminal dimerization/docking domain contained in the 
RII dimer (27-29).  While almost all AKAP PKA-binding sites may be modeled as an 
amphipathic helix motif, they share little primary sequence similarity, making 
identification of new AKAPs via BLAST or genomic searches unfeasible.   Depending 
on the type of PKA an AKAP targets, AKAPs are defined as Type I, Type II or Dual 
AKAPs. As their names suggest, Type I AKAPs bind to Type I PKA holoenzyme, Type 
II AKAPs bind to Type II PKA holoenzyme, and Dual AKAPs are capable of binding to 
both types of PKA (30). Some well-characterized exclusive RII binding AKAPs are 
AKAP79 and mAKAP (25, 31). Even though RII binding AKAPs are more common, 
there are AKAPs that exclusively bind to RI, such as integrin α4 and myosin 7a (32). The 
third category of AKAPs interacts with both RI dimers and RII dimers. Some examples 
are Ezrin (AKAP78), BIG-2, D-AKAP1 and D-AKAP2 (25, 33). It has been observed 
that AKAPs have a 10-100 fold higher affinity to bind to RII as compared to RI (30). 
This difference in binding arises due to specific amino acid differences in the RI and RII 
N-terminal helix that interacts with the AKAP amphipathic helix for docking of the dimer 
(25). 
Targeting of AKAPs at a sub-cellular location occurs by virtue of protein-protein, 
protein-lipid, or lipid-lipid interactions. The protein-protein interactions that mediate 
AKAP localizations occur via a specific domain on the AKAP. For example, mAKAP 
has three spectrin like repeats that help localize this AKAP to the peri-nuclear region via 
its association with Nesprin-1α (34, 35). Yotiao interacts with its target protein, the 
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KCNQ1 (voltage gated potassium channel) channel, by a leucine zipper coiled-coil motif 
on the channel and specific N-terminal and C-terminal domains on Yotiao (36, 37). An 
example of protein-lipid interaction is exhibited by AKAP79, which directly interacts 
with phospholipids to be localized to the plasma membrane. Additional protein-protein 
interactions direct the AKAP to specific ion channels, such as the L-type Ca-channels or 
M-type K-channels (38). Lastly, Gravin (AKAP250) is localized to the plasma membrane 
by virtue of N-terminal myristoylation along with presence of phospholipid binding 
motifs (39). These targeting mechanisms help an AKAP localize PKA to its substrate in 
specific cellular compartments. 
Efficient compartmentalized cAMP signaling by AKAPs is mediated by their 
capacity to assemble multi-molecular complexes. AKAPs perform this function by 
assembling a multivalent complex that may consist of other kinases, ACs (Adenylyl 
Cyclase(s), PPs (Protein Phosphatases), PDEs (Phosphodiesterases), and various other 
signaling proteins, depending on the requirement of the cell. The first AKAP-mediated 
protein complex was discovered for AKAP79. Yeast-2-hybrid analysis of the complex 
found that it associates not only with PKA, but also with PKC (Protein Kinase C) and 
PP2B (Protein Phosphatase 2B, a calcium calmodulin dependent phosphatase) (40, 41). 
Another example of a large complex assembly will be AKAP450. AKAP450 targets a 
complex consisting of PKA, PKC, polynucleotide kinase, PP2A, PP1, and PDE4D3 to 
centrosomes (32). Other examples are AKAP-Lbc, mAKAP, AKAP220, Gravin, and 
WAVE. These multi-protein complexes are involved in signal integration of various 
pathways for a particular function and for regulation of substrate phosphorylation status. 
Figure 1.5 shows some cardiac specific AKAP complexes.  
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Figure 1.5: AKAP complexes found in the heart. 
Diagram represents few important AKAP complexes that have been detected in cardiac 
myocytes. Shown here is a cardiac myocyte with AKAP complexes associated with 
various cellular micro-domains. Example of plasma membrane channel associated 
AKAPs are Yotiao, AKAP79 and AKAP18α. AKAPs associated with cytoskeletal 
structures are Myospryn and AKAP Lbc. An example of cytoplasmic AKAP is D-
AKAP2. Sarcoplasmic reticulum associated AKAPs are AKAP18γ and mAKAP. 
mAKAP also attaches to the nuclear envelope. 
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In cardiac myocytes, AKAP79, Yotiao and AKAP18α regulate function of ion 
channels located on the plasma membrane, whereas mAKAP and AKAP18δ have been 
shown to regulate calcium channels on the sarcoplasmic reticulum (42, 43). Other 
important AKAPs in a cardiac myocyte include AKAP-Lbc, myosryn, and D-AKAP2. 
These are cytosolic AKAPs and have functions related to activation of transcription 
factors (AKAP Lbc), muscle contraction (myospryn) and endocytic cycling (D-AKAP2) 
(44-46). 
Some insight into the mechanism involved in the assembly of multi-molecular 
complexes is available to us. One hypothesis is that AKAPs can bind to multiple proteins 
by virtue of native unfolded regions in their protein structure (47-49). Another interesting 
mechanism is interaction of AKAPs with other scaffolding proteins. For example, 
AKAP150 interacts with PSD-95 (Post Synaptic Density protein 95) to assemble the 
necessary molecules required for endocytosis of synaptic AMPA receptors (50). KSR-1 
(Kinase Suppressor of Ras 1) scaffold, networks with AKAP-Lbc to mobilize cAMP 
responsive control of the ERK (Extracellular signal-Regulated Kinase) signaling pathway 
(51). A third possible mechanism to construct multitude of AKAP complexes is AKAP 
oligomerization.  AKAP-Lbc has been reported to form homo-dimers (52).  This homo-
dimerization is required for regulation of Rho-GEF activity of AKAP-Lbc. It was also 
found that AKAP79 dimerizes and this interaction is principally dependent on its C-
terminus sequence. However, limited dimerization using the N-terminal domain was 
observed as well. It is thought that this dimerization increases the stoichiometry of 
phosphatase association with the AKAP (49). Another homo-oligmer forming AKAP is 
Gravin (AKAP12) (47), although the function of Gravin oligomerizaiton is still unknown. 
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To summarize, AKAPs seem to adopt different mechanisms for efficient signal relay and 
execution. One of the mechanisms that they use is self-interaction. Discovery of the 
functional significance of AKAP oligomerization is an advancing field of research. 
 
1.3.  REGULATION OF PP1 FOR PKA SIGNAL PROPAGATION  
Kinases regulate a plethora of cellular processes by phosphorylating various 
important substrates in a cell. Over 98% of the phosphorylations in a cell are on a 
serine/threonine residue while only around 2% of these phosphorylations occur at 
tyrosine residues (53). Hence, the role of serine/threonine phosphatases in regulating the 
phosphorylation states of proteins is critical. It is predicted that the human genome 
encodes for over 420 serine/threonine kinases but only about 40 serine/threonine 
phosphatases (54-57).  Therefore, regulation of phosphatase specificity would be very 
important for achieving proper substrate dephosphorylation.  Like kinases, the specificity 
of phosphatase activity in the context of its substrate is highly regulated. This is achieved 
by scaffolding proteins that anchor the phosphatase in a specific cellular domain and/or 
by endogenous phosphatase inhibitors that maintain the phosphatase in an inactive form 
when activity is not required (58, 59). The combination of accessory proteins regulating 
the phosphatase activity is not the same in all situations and this alteration in the 
combination of proteins regulates the substrate specificity of phosphatases.   
Protein Phosphatase 1 is one the most well understood serine/threonine 
phosphatases in the mammalian system (60).  It is a metallo-enzyme that requires di-
valent cation for its activity (61). Mammals have three different genes that lead to 
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expression of four distinct gene products: PP1α, PP1β/δ, PP1γ1 and PP1γ2 (62). The 
human genome has an additional splicing event in PP1α gene product, giving rise to 
PP1α1 and PP1α2 isoforms (63, 64).  PP1 isoforms do not have any substrate distinction 
when examined under in vitro conditions. But, in cells, each isoform has a distinct 
substrate profile and a specific tissue distribution (65, 66).  The molecular weight of PP1 
isoforms is around 37kDa and the isoforms have a 90% amino acid sequence similarity. 
The 10% difference arises due to differences in N- and C-terminus sequence of the 
isoforms, which also dictates specific interaction of each isoform with a specific 
regulatory protein (58, 67).  There are over 200 bonafide or putative regulatory proteins 
known which can interact with 4 PP1 isoforms in mammalian cells (66). These regulatory 
proteins dictate the localization and substrate specificity of the PP1 isoforms.  
PP1 Binding Proteins (PBPs) interact with PP1 with the help of specific amino 
acid motifs. Most PBPs have four to eight peptide domains for PP1 binding, whereas PP1 
itself has over 30 non-.overlapping binding motifs on its surface for interacting with 
PBPs (65).  Shown in the figure 1.6 is the common structural motif, the RVxF motif that 
most PBPs contain (68). The RVxF motif interacts with a hydrophobic groove on the PP1 
surface (shown by a green hexagon) not far from the PP1 catalytic site (red 
parallelogram) (69, 70). Binding of the RVxF motif alone to PP1 does not bring about 
any change in PP1 conformation, but it carries out the important function of bringing the 
PBPs in close proximity to PP1 to allow for secondary interactions (71).  Also shown in 
figure 1.6 are the secondary motifs such as the SILK motif and the MyPhoNE motif, 
found on multiple PBPs for PP1 regulation (68, 72). The functions of the secondary   
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Figure 1.6: Diagram depicting binding of PP1 regulatory proteins to different 
domains on PP1 surface.  
Represented in light green is the PP1 enzyme with few of the known binding surfaces on 
the enzyme. PP1 binding protein (PBPs) A, B, C and D are represented here depicting the 
motifs they cover for binding to PP1. A: I-2 interaction with PP1 occurs via RVXF and 
two other motifs called as IDoHA and SILK, B: MyPT1 interaction with PP1 requires 
RVXF and MyPhone motif, C) Spinophilin interaction with PP1 is mediated by RVXF 
and SpiDoC, D) Spinophilin competes with I-2 for occupying the RVXF binding grove 
on PP1. This occurs when Spinophilin and I-2 bind to PP1 together. 
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binding motifs vary on a case-by-case basis. In the examples explained in figure 1.6, the 
SILK motif which consists of consensus amino acid sequence K-[GS]-I-L-K, serves to 
bind I-2 (Inhibitor-2) to PP1 enzyme without causing conformational or catalysis changes 
to the latter (70, 73). On the other hand, the MyPhoNE motif (Myosin Phosphatase N-
terminal Element) found in MyPT1 (Myosin Phosphatase Targeting subunit 1) 
contributes to PP1 substrate selection (72). MyPhoNe motif consists of the R-X-X-Q-
[VIL]-[KR]-X-[YW] consensus sequence (72). Other secondary binding motifs found in 
PBPs consist of the SpiDoc (Spinophilin Docking site for C-terminal groove) found in 
Spinophilin (74). In addition to RVXF and SILK motifs, I-2 also has the conserved 
IDoHA motif (Inhibitor Docking site for Hydrophobic and Acidic groves) that binds to 
the PP1 active site (73).  In summary, PBPs contain at least two domains that interact 
with PP1. The first, RVxF, provides a high affinity binding domain that allows for the 
initial interaction.  Secondary domains, such as SILK and MyPhoNE, provide various, 
domain-dependent functions such as substrate definition and regulation of PP1 activity.   
Since PP1 isoforms differ in their N- and C-terminal amino acid sequences, 
another important category of secondary binding motifs includes PBPs that specifically 
interact with either the PP1 N- and/or C-terminus. For example, MYPT1 binds to PP1β/δ 
C-terminus (72). This governs PBP interaction in a PP1 isoform specific manner adding 
another level of specificity.  
It is interesting that PBPs, when not bound to PP1, are either unstructured proteins 
altogether or have an unstructured domain that interacts with PP1 (75). A bioinformatics 
protein prediction analysis program called IUPRED predicts that about two-thirds of the 
total PBPs having the RVxF motif, are either unstructured or have unstructured domains 
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of at least 100 amino acids (75). A possible explanation for this phenomenon could be 
that having an unstructured protein might be crucial for formation of a large PP1 
interaction surface to tightly regulate function of the PP1 holoenzyme. Unstructured 
PBPs have an added advantage of intrinsic flexibility, enabling them to behave as 
scaffolds for other proteins to bind.  
PP1 inhibition is an important facet in PP1 activity regulation.  Potent inhibitory 
drugs such as microcystin-LR, nodularin-R and tautomycin have been well characterized 
(76, 77). These molecules inhibit PP1 activity by binding to the PP1 active site. On the 
other hand, multiple endogenous PP1 inhibitors are PBPs and require binding via the 
RVxF motif as well as secondary motif(s) to inhibit PP1. Examples of the well-
characterized endogenous protein inhibitors of PP1 are DARPP32 (Dopamine and cAMP 
regulated PhosphoProtein 32), I-1 (Inhibitor-1) and I-2 (inhibitor-2). These inhibitors 
have the RVxF motif and secondary binding motifs to cause PP1 inhibition (60). 
Additionally, some inhibitors, like DARPP-32 and I-1 require phosphorylation in order to 
inhibit PP1 (67).  Other inhibitors, such as I-2, do not require a phosphorylation event to 
inhibit PP1, but inversely need a phosphorylation event to eliminate PP1 inhibition (78).  
In both cases, binding of the inhibitor to the phosphatase is not dependent on inhibitor 
protein phosphorylation event. 
In addition to being regulated at two different levels i.e by tissue specific 
expression and targeting and inhibition by PBPs, PP1 is also regulated by scaffold 
proteins that direct substrate specificity for this enzyme. Unlike PP1 inhibitors and 
targeting proteins, substrate-specifying proteins act in a more sophisticated manner. A 
number of substrate specifiers are targeting or inhibiting PBPs as well.  Substrate 
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specifying PBPs can use positive or negative substrate selection mechanisms.   Positive 
selection occurs when a substrate specifier protein increases PP1 activity towards a 
specific substrate and negative selection occurs when PP1 activity is selectively reduced 
for a subset of substrates (65). The glycogen interacting G-subunits (GM and GL) 
involved in PP1 targeting for glycogen metabolism regulation exemplify both positive 
and negative substrate selection (67, 71). As shown in figure 1.7, in the presence of 
insulin, these scaffolds inhibit PP1 activity towards glycogen phosphorylase (loss of 
activity), but promote PP1 mediated dephosphorylation of glycogen synthase (gain of 
activity) required for glycogen synthesis (58, 79, 80).   
Another interesting example of a PP1 substrate specifier that was recently 
described is the Repo-Man protein (81). Repo-Man is a chromosomal bound protein that 
interacts with PP1. In this particular study, Repo-Man was discovered to restrict the 
activity of PP1 to two phosphorylation sites of histone H3, threonine-3 and threonine-11, 
although there are other phosphorylated amino acids on this protein (threonine-10 and 
serine-28) that are not dephosphorylated by Repo-Man-bound PP1. These specific de-
phosphorylations are required for normal cell division. The molecular mechanism behind 
this phenomenon is still under investigation.   
To summarize, PP1 isoforms have a tissue specific expression for their activity 
regulation. Importantly, the permutation and combination of the regulatory proteins 
(subunits) with endogenous PP1 inhibitors and substrate specifiers makes PP1 activity 
highly specific within a cellular environment. 
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Figure 1.7: Positive and negative regulation of PP1 activity by substrate-specifying 
glycogen targeting subunits.  
In the presence of Insulin, glycogen synthesis is promoted. PP1 is targeted to glycogen 
particles in tissue by glycogen targeting proteins called as GM and GL. Glycogen 
synthesizing enzyme called glycogen synthase needs to be dephosphorylated for it to be 
activated (blue arrows), whereas glycogen breakdown is inhibited by de-activating 
glycogen phosporylase by preventing its dehosphorylation by PP1. This exemplifies PP1 
activity regulation by substrate specifying scaffolds GM and GL that direct its activity only 
to glycogen synthase and not to glycogen phosphorylase. 
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1.4.  REGULATION OF PP1 BY I-1  
Inhibitor-1 protein was discovered in 1976 and was the first endogenous PP1 
inhibitor to be identified (82).  Unlike PP1, which can be transported into the nucleus, 
(83), I-1 is a cytoplasmic protein that is widely expressed in mammals including heart 
and skeletal muscle (84, 85). I-1 is only 171 amino acids long with a theoretical 
molecular weight of 19kDa (86, 87). I-1 expression is vertebrate specific and the N-
terminus of the protein is highly conserved among species (58, 86).  In humans, I-1 
mRNA is alternatively spliced to give rise to three variants: full length I-1, I-1α and I-1β 
(88). The specificity of each isoform to independent cellular processes is unknown at 
present. 
Following the isolation of I-1 from rabbit skeletal muscle, it was found that nano-
molar concentrations of purified PKA phosphorylated I-1 could inhibit PP1 whereas 
micro-molar concentration of unphosphorylated I-1 could not (89). The binding affinity 
of I-1 for PP1 is very low when I-1 is dephosphorylated.  Phosphorylation by PKA 
dramatically increases the binding affinity, resulting in inhibition of phosphatase activity 
(90, 91). Point mutation experiments on I-1 amino acid sequence found that I-1 
phosphorylation by PKA at threonine-35 is absolutely required for I-1 mediated 
inhibition of PP1 (87). Therefore, cAMP dependent I-1 phosphorylation leads to a feed 
forward mechanism for enhancing substrate phosphorylation by mediating PP1 inhibition 
and by PKA mediated substrate phosphorylation. Inactivation of I-1 towards PP1 
inhibition occurs via its dephosphorylation at the threonine-35 site by PP2A and PP2B in 
rat neonatal cardiac myocytes (92). Furthermore, a second phosphorylation event that 
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regulates I-1 activity towards PP1 is PKC mediated I-1 phosphorylation at serine-67 and 
threonine-74 in heart cells. These phosphorylation events cause decline in I-1 mediated 
PP1 inhibition (93).  
  Since the T35 phosphorylated I-1/PP1 complex crystal structure has not been 
solved yet, our understanding of structural basis of I-1 mediated PP1 inhibition comes 
from NMR studies of this complex (94). Inability to perform X-ray crystallography of 
this complex can be primarily attributed to intrinsically disordered nature of the I-1 
protein. NMR data (represented in figure 1.8) shows that unphosphorylated I-1 can 
interact with PP1 at a different site than the catalytic core (yellow rhombus in the PP1 
enzyme in the figure). On the other hand, NMR study using T35 phosphorylated I-1/PP1 
complex suggests that phosphorylation of I-1 pushes the I-1 protein inside the catalytic 
core of PP1, causing phosphatase inhibition (also shown in figure 1.8) (94). I-1 associates 
with PP1 with the help of a RVxF like motif, KIQF present in the N-terminus of the 
protein (amino acids 8-12). While this motif allows for the interaction of the two proteins, 
it does not play a role in the inhibition of the phosphatase by the inhibitor. Inhibition can 
only occur when I-1 is phosphorylated at T35 by PKA (87, 94, 95).  
  
 
 
 
 
  22 
  
 
 
Figure 1.8: Regulation of PP1 by PKA phosphorylated I-1. 
Figure represents the I-1 mediated PP1 regulation after PKA mediated phosphorylation of 
I-1. Shown on the left is PP1 enzyme (hexagonal dull orange) with its catalytic domain 
(yellow rhombus). Unphosphorylated I-1 (lavender polygon) can associated with PP1 but 
does not inhibit its activity. Upon PKA phosphorylation, I-1 goes through conformational 
changes that moves the I-1 phosphorylated region into the PP1 catalytic domain leading 
to PP1 inhibition. It has been found in cardiac myocytes that this process can be reversed 
by phosphatases called as PP2A and PP2B. 
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1.5.  REGULATION OF PP1 BY AKAPS 
Study of molecular mechanism of PP1 regulation by AKAPs is an emerging field. 
Multiple AKAPs have been shown to interact with PP1 for regulation of substrate de-
phosphorylation. This is achieved by localizing the phosphatase in close proximity to its 
substrates, but work specifically focusing on molecular interactions of PP1 and AKAPs 
for PP1 regulation is in progress (96). One of the AKAPs that binds to PP1 and has been 
studied in this context is AKAP149. AKAP149 is a human AKAP that has been shown to 
play an important role by recruiting PP1 for nuclear envelope reassembly during mitotic 
exit. AKAP149 has the PP1 binding motif RVXF (K153GVLF157) and mutation of the 
binding motif disables this AKAP from binding to PP1 (97). Moreover, AKAP149 also 
inhibits PP1 activity against phosphorylase a in vitro but enables PP1 to dephosphorylate 
B-type Lamin in vivo, suggesting that AKAP149 also acts as a substrate specifying 
scaffold for PP1 (98). Furthermore, serine phosphorylation around the RVXF motif of 
AKAP149 itself is a mechanism for reversal of PP1 binding to the AKAP. The 
phosphorylation at S151 or S159 can occur by PKA or PKC bound to AKAP149 but the 
release of PP1 occurs only when one of the serine residues is phosphorylated by PKC 
associated with this complex. This suggests a model where PP1 is bound to the AKAP for 
a specific purpose and then released by activity of another kinase bound to the complex 
(99).  
 Another interesting example of PP1 regulation by an AKAP is that of AKAP220. 
AKAP220 not only has the consensus PP1 anchoring motif (KVxF), but also has C-
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terminal motifs (2 or more,) that are involved in PP1 inhibition by binding to the PP1 
active site [Figure 1.9]. Moreover, addition of RII dimer to AKAP220-PP1 reaction 
mixture enhances the ability of the AKAP to inhibit PP1 by four folds using 
phosphorylase a as a PP1 substrate. However, the molecular mechanism for RII-mediated 
inhibition of AKAP220-bound PP1 is not known.  It is a very exclusive case of PP1 
inhibition by an AKAP, as the PKA catalytic subunit does not participate in any 
phosphorylations that may inhibit the phosphatase.  Instead, the authors hypothesize that 
binding of the regulatory subunit of PKA to the AKAP causes conformational changes in 
the AKAP that potentiate AKAP220 for PP1 inhibition (100).  
 A more recent discovery was the AKAP79 mediated inhibition of PP1 by our 
laboratory. Previously, AKAP79 was recognized for its PP2B (calcineurin) anchoring and 
inhibition (40). In a recent report, Le et al. showed that AKAP79 had a consensus PP1 
binding motif in the first 44 amino acids. Furthermore, deletion of this domain did not 
attenuate PP1 binding to AKAP79 suggesting the presence of another PP1 binding 
domain. Mapping experiment showed that the second PP1 binding domain on AKAP79 
exists between amino acids 150-250. Furthermore, this second PP1 binding domain not 
only bound the phosphatase but also inhibited its catalytic activity towards a generic 
substrate. On the other hand, AKAP79 bound PP1 was active in the context of a specific 
PP1 substrate found in the brain, PSD95. Based on these observations, the study 
concluded that AKAP79 acts as a PP1 anchoring protein that defines the substrate 
selectivity of this phosphatase (101).  
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Figure 1.9: PP1 regulation by AKAP220. 
AKAP220 has mutiple PP1 binding sites. The concensus PP1 binding motif of AKAP220 
KVXF is located in the N-terminus of the protein but has no effect on PP1 inhibition. The 
C-terminus of the protein has multiple PP1 binding moifs (not completely defined yet) 
that can bind to PP1 and inhibit its activity (A).  PP1 inhibition is greatly increased by 
AKAP220 upon RII dimer binding to the AKAP. RII binding causes conformational 
changes to the AKAP increasing its affinity for PP1 and hence increased inhibition. RII 
dimer does not alter KVXF motif mediated PP1-AKAP220 interaction. 
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1.6.  IMPORTANCE OF PP1 AND I-1 IN DISEASE 
One of the hallmarks of a failing heart is reduced phosphorylation of multiple 
PKA targets which includes PLN (102, 103). PLN is a 6 kDA protein found in the SR 
membrane and has been widely recognized as a negative regulator of calcium uptake 
pump on the SR membrane, SERCA (Sarcoplasmic/Endoplasmic Reticulum Calcium 
ATPase) (104).  As illustrated in Figure 1.10A, in its dephosphorylated state PLN binds 
to SERCA, and reduces its affinity for calcium, ultimately resulting in less calcium being 
pumped across the membrane into the SR. Under β-adrenergic stimulation and the 
increase in cAMP and PKA activity (Figure 1.10B), PLN is phosphorylated.  
Addtionally, PKA also phosphorylates I-1 to inhibit PP1 activity, allowing for enhanced 
PLN phosphorylation. These two actions result in the loss of PLB/SERCA interaction 
and an increase in pump activity (105-107).  After the stimulatory conditions have waned 
off, PLN is dephosphorylated by PP1 to restore contractility to basal state (108).  
The reduction in PLN phosphorylation in both human and animal models of heart 
failure has been attributed to both upstream processes, such as reduced cAMP generation 
in the cardiac myocyte, and downstream processes, such as increased phosphatase 
activity (109-111). It was discovered that the increase in PP1 activity is regulated at the 
micro-domain level because while PLN was significantly dephosphorylated, other PP1 
targets were not (37). Further work attributed the increased PP1 activity to a decrease in 
I-1 expression (mRNA and protein level decreased by 60%) combined with decreased  
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Figure 1.10: Regulation of Phospholamban (PLN) by PP1. 
A) Unphosphorylated PLN binds to SERCA pump and reduces its affinity for calcium 
leading to reduced calcium uptake into SR. B) β-adrenergic activation leads to PLN 
phosphorylation by PKA preventing its binding to the SR calcium uptake pump, SERCA. 
SERCA when not bound by PLN, has high affinity for calcium leading to efficient calium 
uptake inside SR. This is also promoted by simultaneous inhibition of PP1 by PKA 
phosphorylated I-1. These events are necessary for maintaining cardiac responses under 
which cardiac output has to be increased such as exercise.  
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percentage of total I-1 that was phosphorylated at T34 (about 80% reduction) in human 
hearts as well as animal models of heart failure (112-114).  
Furthermore, it has also been identified that in cardiac myocytes, I-1 undergoes 
PKC mediated phosphorylation at amino acids serine-67 and threonine-74. These 
phosphorylations prevent cAMP mediated I-1 phosphorylation and are not inhibitory to 
PP1 activity. This is important under conditions where high levels of PKC activity 
attenuate the PKA effect due to lack of I-1 inhibition (93, 115).  It is proposed that this 
might be the mechanism by which I-1 mediates the cross talk between the PKA and PKC 
pathways under normal conditions for regulation of cardiac function. [Figure 1.11]. 
Under pathological conditions, PKA is downregulated in cardiac myocytes whereas PKC 
is upregulated, causing a total reduction in I-1 phosphorylation at threonine-35 leading to 
loss of optimal PP1 inhibition (93, 112, 114, 116). Furthermore, PKC mediated I-1 
phosphorylation also prevents I-1 from being accessible for PKA phosphorylation (93, 
117). Together the PKA and PKC mediated I-1 phosphorylation changes lead to a high 
PP1 activity in diseased hearts, which has been shown to be one of the reasons for heart 
failure (112, 118-121) [Figure 1.12]. Following this observation, various mice models of 
heart failure were developed in order to fully understand the role of I-1 in regulation of 
heart function and to explore the possibility of using I-1 as a novel drug target.  
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Figure 1.11: Regulation of PP1 by I-1 for normal cardiac function. 
 
Pictorial representation of I-1 regulation by PKA and PKC has been shown. PKA 
mediated phosphorylation of I-1 helps in PP1 suppression to enhance cardiac function. 
PKC mediated phosphorylation of I-1 prevents I-1 mediated PP1 inhibition leading to 
depressed cardiac function. In a healthy heart, both PKA and PKC mediated 
phosphorylations maintain PP1 activity at optimum levels.  
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Figure 1.12: Misregulation of PP1 due to alteration of I-1 phosphorylation. 
Diagram shows change in I-1 phoshorylation in a diseased heart. Decreased PKA activity 
in cardiac myocytes subjected to heart failure promoting conditions, causes reduction of 
PKA mediated I-1 phosphorylation leading to loss of PP1 inhibition. Decline in PP1 
inhibition is further promoted by increased PKC activity in disease condition. PKC 
mediated phosphorylation of I-1 prevents I-1 from inhibiting PP1 and also makes I-1 
unavailable for PKA phosphorylation. Together these changes in I-1 phosphorylation 
promote a significant increase in PP1 activity causing progression of heart disease into 
heart failure.  
  31 
  
 
Early investigations revealed that heart specific overexpression of I-1c (N-
terminus of I-1 having the PKA phosphorylation site was expressed with a threonine-35 
to aspartate mutation for constitutive PP1 inhibition) in mice protected them against heart 
failure (122, 123). Recently it was also demonstrated that I-1c overexpression inhibits 
cardiomyocyte apoptosis induced by chronic beta agonist administration (124). These 
results suggested that targeting over-expression of I-1 could be a potential therapy for 
patients.  However, contradictory to these results, another group of investigators have 
reported that I-1 knockout mice are protected against heart failure using a similar heart 
failure model (125).  Further study demonstrated that conditional over-expression of I-1c 
on I-1 knockout background produced contractile dysfunction under administration of 
catecholamines and this effect could be reversed by turning off I-1c expression (126). 
Importantly, I-1c overexpressing mice developed cardiomyopathies with age unlike 
normal aging heart (126, 127). The lack of concurrent results from these studies questions 
the therapeutic potential of I-1 (128).  
The inconsistent results obtained by different groups requires further investigation of 
I-1 mediated inhibition of PP1 in cardiac myocytes. Furthermore, even though the 
mechanistic details of I-1 inhibition of PP1 are known, it is not known which factors or 
proteins regulate these two proteins for their micro-domain localization (both these 
proteins are concentrated at SR, described above). The work presented in this thesis is an 
effort towards answering these questions. 
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1.7.  AKAP18 AS A MODEL AKAP 
AKAP18 (also called as AKAP7, based on gene name) was independently 
discovered in two separate laboratories (129, 130). Several studies before that had shown 
that injecting inhibitor peptides that disrupt AKAP-PKA binding attenuates membrane 
channel function suggestive of PKA being anchored at the cell membrane for regulation 
of L-type Ca channels in cardiac and skeletal muscle.  The AKAP that was showing this 
effect was cloned and identified as AKAP15/18 (129, 130). Immediately after this other 
AKAP18 isoforms were discovered. These are shown in Figure 1.13. It was found that 
alternative splicing leads to evolution of three isoforms: the originally discovered short 
isoform AKAP18α, the newly cloned short isoform AKAP18β, and a long isoform 
AKAP18γ.  
The two short isoforms are almost identical except that AKAP18β, a little longer 
than AKAP18α, had a 23 new amino acids inserted at its N-terminus. The N-terminal of 
AKAP18γ was identical to the short isoforms except that it lacked the membrane 
targeting lipid modification motif that the short isoforms had. Moreover, AKAP18γ had 
an extended amino acid sequence between the identical N and C-terminus it shared with 
the shorter isoforms. Transfection studies using GFP tagged AKAP18 plasmids showed 
that the short isoforms were targeted to the membrane while AKAP18γ (long isoform) 
was targeted to the cytoplasm (131). A few years after these discoveries, another long 
isoform of AKAP18, called as AKAP18δ was discovered in the renal principal cells 
where it augments vasopressin-induced aquaporin 2 shuttling.  AKAP18δ is the longest 
of the four AKAP18 isoforms with 356 amino acids while AKAP18γ has 326 amino  
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Figure 1.13: AKAP18 isoforms. 
Linear diagram showing AKAP18 isoforms. AKAP18 isoforms are splice variants of 
AKAP18 gene and share significant protein sequence homology. The short splice variants 
are AKAP18α and AKAP18β. They are localized to the plasma membrane by virtue of 
post-translational lipid modifications. AKAP18α is directed to L-type Calcium Channel 
(LTCC) for channel phosphorylation. The larger isoforms are AKAP18γ and AKAP18δ. 
These are cytoplasmic and get localized to cellular domains via protein-protein 
interactions.  The large isoforms have been shown to localize to the Sarcoplasmic 
Reticulum in cardiac myocytes and regulate Phospholamban (PLN) phosphorylation. 
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acids, followed by AKAP18β and AKAP18α, which have 104 and 81 amino acid residues 
respectively (132).  
AKAP18α undergoes N-terminal myristoylation/palmitoylation in order to localize 
to the plasma membrane. At the plasma membrane, it interacts with L-type Ca channel in 
skeletal muscle and heart and it interacts with the Na-channel in the brain to modulate 
channel activity via PKA mediated phosphorylation of these channels. AKAP18β is only 
23 amino acids longer than AKAP18α due to an insertion at its N-terminus, but both 
AKAP18α and AKAP18β exhibit different expression patterns when transfected into 
MDCK cells. AKAP18β is targeted to the apical plasma membrane in polarized MDCK 
cells whereas AKAP18α is localized to the basolateral and apical plasma membrane in 
these cells (130, 131). The physiological function of AKAP18β still needs to be defined.  
AKAP18γ has a nuclear localization signal, which targets it to the nucleus in mouse 
oocytes. This is a particularly interesting report as the data showed species specific 
differences in AKAP18γ sequence leading to difference in PKA holoenzyme binding and 
also localization of the AKAP. Human AKAP18γ is predominantly a PKA type II 
binding AKAP and is localized in the cytoplasm via protein-protein interaction. In case of 
mouse oocytes, AKAP18γ has an additional RGD (Arginine-Glycine-Aspartic Acid) 
sequence which enables integrin binding. Also, AKAP18γ in mouse oocyte is a PKA type 
I binding AKAP, which is attributed to predominant expression of PKA type I in these 
cells. The PKA binding domain of human pancreatic and mouse oocyte AKAP18γ is 
identical (133). AKAP18δ was discovered in the renal cells but later it was found to be 
important in regulating phosphorylation of PLN (134). A recent study elucidated that the 
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SR localization of PKA anchored to AKAP18δ in rats is carried out in humans and mice 
using AKAP18γ, suggesting that apart from tissue specific variations, there can be 
species specific variations in expression of AKAP18 isoforms (135). Interestingly, it has 
been shown that in INS-1E cell line, silencing of AKAP18α or AKAP18γ leads to 
corresponding decrease or increase in insulin secretion upon glucose sensitization. This is 
a unique example of an AKAP whose isoforms may have opposite effect on a 
physiological process (136). 
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Goals and summary of results of the thesis work: 
 
In summary, previous work demonstrated PLN phosphorylation is the key 
mechanism used by the heart to enhance the speed of relaxation. By tethering PKA to 
PLN in cardiac myocytes, AKAP18 mediates this phosphorylation event. However, in 
the failing heart, PLN is hypo-phosphorylated.  This is correlated with a decrease in I-
1 phosphorylation by PKA and increased PP1 activity. I investigated if there is an 
AKAP that anchors I-1 and regulates its PKA mediated phosphorylation required for 
PP1 inhibition [Figure 1.14]. My thesis work demonstrates that AKAP18γ can bind to 
I-1 and enhance its PKA mediated phosphorylation. Before my thesis work, there were 
no reports suggesting direct interaction between a PP1 inhibitor protein and an AKAP, 
even though PP1 has been found to interact with various AKAPs.  Moreover, the 
AKAP18γ-I-1 complex can inhibit PP1 in a PKA dependent manner. This is an 
important finding as AKAP18γ not only binds to I-1, it regulates its function of PP1 
inhibition. These results suggest that AKAP18γ localizes I-1 to the SR for PP1 
regulation. Furthermore, I also investigated the mechanism that may be involved in 
efficient PKA mediated PLN and I-1 phosphorylation by AKAP18γ. We found that 
AKAP18γ oligomerizes. Oligomerization of AKAP18γ should enhance substrate 
phosphorylation impacting both PLN and I-1. Together, these findings show that 
AKAP18γ organizes a multi-molecular complex to regulate PLN phosphorylation, by 
directly enhancing the associated PKA activity and by inhibiting PP1 via I-1. Hence, 
AKAP18γ establishes itself as a bi-directional regulator of protein phosphorylation.   
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Figure 1.14: Diagram showing the premise of hypothesis.  
AKAP18γ/δ is localized at the Sarcoplasmic Reticulum (SR) in cardiac myocytes to 
mediate PLN (phospholamban) phosphorylation. This AKAP is localized to the 
membranous compartment by virtue of its direct interaction with PLN. PP1 is also known 
to be localized at the SR for PLN dephosphorylation. I-1 has been shown to be 
concentrated at the SR for PP1 regulation. I-1 becomes a potent PP1 inhibitor after PKA 
mediated phosphorylation. We propose that the localized I-1 phosphorylation required for 
PP1 inhibition at the SR is regulated by an AKAP. 
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2.1. ABSTRACT 
Inhibitor-1 (I-1) is phosphorylated on threonine residue 35 (Thr-35) by the cAMP-
dependent protein kinase (PKA), inducing the potent inhibition of the serine-threonine-
specific protein phosphatase 1 (PP1).  We now report that the formation of a signaling 
complex containing PKA and I-1 by the A-kinase anchoring protein, AKAP18, facilitates 
this regulation in cells.  AKAP18 directly bound I-1, and AKAP18/I-1 complexes were 
isolated from both rat heart extract and transfected heterologous cells.  Importantly, 
prevention of PKA binding to the AKAP18 scaffold decreased I-1 phosphorylation by 
48% in cells.  Moreover, the I-1 target PP1 was also associated with AKAP18 complexes. 
The cAMP-mediated inhibition of phosphatase activity was contingent upon PKA 
binding to the scaffold. These observations reveal an additional level of complexity in 
PP1 regulation due to its association with AKAP18 multi-molecular signaling complexes, 
and suggest that targeting of AKAP18 complexes may be an alternative method to alter 
phosphatase activity and modulate specific substrate dephosphorylation. 
 
2.2. INTRODUCTION 
Protein phosphorylation is a key regulator of cellular physiology that affects 
essentially all biological processes.  Despite our vast knowledge of the consequences of 
protein phosphorylation, the molecular mechanisms that confer specificity to the enzymes 
controlling this post-translational modification are not well understood, especially for the 
handful of phosphatases that catalyze the dephosphorylation of protein substrates (57, 
67).   Seminal investigations have demonstrated that the cell has evolved multiple 
strategies that control the location, activity and substrate specificity of each phosphatase 
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(57, 67).  Current research is focused on the contribution of individual multi-molecular 
signaling complexes to the specificity of intracellular signal transduction. 
The first protein discovered to regulate phosphatase activity was the Protein 
Phosphatase Inhibitor-1 (I-1) (91).  I-1 is a 19 kDa, heat stable protein that was identified 
over 30 years ago as a regulator of glycogen metabolism (91).  While I-1 has no known 
intrinsic catalytic activity, its binding reduces the activity of protein phosphatase 1 (PP1).  
I-1 is highly expressed in the brain, where it plays a role in synaptic plasticity (137, 138).  
Although I-1 is expressed at low levels in the adult myocardium, recent work suggests 
that regulation of PP1 by I-1 at the sarcoplasmic reticulum is required for normal cardiac 
function, as well as for the response of the heart to disease (139, 140). I-1 itself is 
phosphorylated by PKA, PKC and CDK5 (91, 139, 141, 142) and phosphorylation of I-1 
at Thr-35 by PKA induces selective inhibition of PP1 (91, 140). This event is induced by 
β-adrenergic stimulation in cardiac myocytes, and potentiates the phosphorylation of key 
PKA substrates involved in excitation-contraction coupling by preventing their PP1-
mediated dephosphorylation (140).  As excessive PP1 activity resulting from a lack of I-1 
function has been suggested to contribute to heart failure, a more complete understanding 
of the molecular regulation of this phosphatase may aid in the design of novel 
therapeutics to prevent or treat heart disease (93, 118, 122, 125).  
The mechanisms conferring specificity on PKA phosphorylation have been of 
considerable interest in recent years, and research has shown that many PKA targets are 
co-localized with the kinase via the association with A-kinase anchoring proteins 
(AKAP) (4, 42).  These scaffold proteins function to enhance the kinetics and specificity 
of PKA phosphorylation by sequestering the kinase with its target substrates, allowing for 
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spatiotemporal control of cAMP signaling. Importantly, disruption of PKA binding to 
AKAPs in the heart significantly decreases the ability of the kinase to phosphorylate 
many key proteins such as troponin I, the ryanodine receptor and phospholamban (143). 
As I-1 is a target for PKA, we investigated whether an AKAP mediates this event.  
We discovered that I-1 binds the large isoforms of AKAP18 in the heart.  AKAP18 
potentiated the phosphorylation of I-1 by PKA, and disruption of PKA binding to the 
scaffold significantly attenuated Thr-35 phosphorylation in HEK293 cells.  Moreover, 
PP1 was also associated with AKAP18 complexes, and the PKA-dependent inhibition of 
phosphatase activity required PKA-AKAP18 binding. These data imply that AKAP18 
orchestrates the PKA-catalyzed phosphorylation of I-1 in the myocyte, providing an 
additional level of regulation of PP1 activity at the sarcoplasmic reticulum, where the 
large isoforms of the AKAP are enriched. 
 
2.3. MATERIALS AND METHODS 
2.3.1. Antibodies 
The following antibodies were used for immunoblotting: rabbit polyclonal to 
inhibitor-1 (Abcam, 1:10,000), goat polyclonal to AKAP18 (received from Dr. John 
Scott, University of Washington, 1:1000), rabbit polyclonal to GFP (Invitrogen, 1:500), 
rabbit polyclonal phospho-specific antibody against Threonine-35 of I-1 (Cell Signaling, 
1:1000), mouse monoclonal to PP1 catalytic subunit (Santa Cruz Biotechnology, 1:1000), 
mouse monoclonal to myc tag (Santa Cruz Biotechnology, 1:1000), mouse monoclonal to 
PKA RI subunit (BD Bioscience, 1:5000), mouse monoclonal to PKA-RII subunit (BD 
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Bioscience, 1:5000), and mouse monoclonal to PKA catalytic subunit (BD Bioscience 
1:5000).  The following antibodies were used for immunoprecipitations: rabbit polyclonal 
to inhibitor-1 (Abcam, 2ug), mouse monoclonal to PP1 catalytic subunit (Santa Cruz 
Biotechnology, 5ug), mouse monoclonal to PP2A catalytic subunit (Santa Cruz 
Biotechnology, 5ug), goat polyclonal to AKAP18 (received from Dr. John Scott, 
University of Washington, 5ul), mouse monoclonal to myc tag (Santa Cruz 
Biotechnology, 5ug), and mouse monoclonal to PKA-RII subunit (BD Biosciences, 2ug). 
2.3.2. Expression Constructs 
For I-1 constructs, human I-1 was PCR amplified using a cDNA, supplied by Dr. 
Shirish Shenolikar, Duke University, and sub-cloned into the EcoRI-Xho sites of pGEX-
4T1 and pCDNA3. Full-length human AKAP18γ (supplied by Dr. John Scott, University 
of Washington) as well as the AKAP18γ deletion constructs were cloned into either the 
EcoRI-BamHI sites of pEGFP-N1, or the EcoRI-HindIII sites of pET32a.   
 
2.4. EXPERIMENTAL PROCEDURES 
2.4.1. cAMP Agarose Purification 
Rat heart extract was prepared by homogenization of a single rat heart (PelFreeze) 
in 10 ml HSE lysis buffer (20mM HEPES [pH 7.4], 150mM NaCl, 5mM EDTA,1% 
Triton X-100, and protease inhibitors).  Following centrifugation at 12,000g for 20 
minutes at 4°C, 1 ml of supernatant (500ug) was incubated overnight with 60ul of Rp-
cAMPs-agarose (Biolog, Bremen, Germany) in the presence and absence of 100mM 
cAMP (Sigma).  The beads were washed twice with HSE lysis buffer, followed by a high 
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salt wash (20mM HEPES [pH 7.4], 600mM NaCl, 5mM EDTA).  Bound proteins were 
analyzed by immunoblotting. 
 For cAMP agarose pulldowns from HEK293 cells, cells were transfected at 70% 
confluency in 60mm dishes using calcium phosphate.  Cells were harvested and lysed 24 
hours after transfection in 0.5ml of HSE buffer containing protease inhibitors.  Cell lysate 
was added to 60ul of Rp-cAMPs-agarose and bound proteins were isolated as detailed 
above. 
2.4.2. Pulldown Experiments 
Heart extract (1ml) was prepared in HSE buffer as described above and incubated 
overnight with glutathione-resin pre-absorbed with bacterially expressed fusion proteins.  
The beads were then washed as described and bound proteins were identified by 
immunoblotting. Alternatively, for pulldown experiments using purified proteins, GST 
fusion proteins were incubated with S-tagged purified AKAP18 fragments bound to S-
protein agarose in HSE buffer lacking EDTA.  After an overnight incubation, beads were 
washed 3X in the HSE buffer and associated proteins were identified by immunoblot. 
2.4.3. Immunoprecipitation 
For immunoprecipitation of AKAP18 constructs from heterologous cells, HEK293 
cells were transfected at 70% confluency using the calcium phosphate method. 24 hours 
post transfection, cells were treated with 1uM Isoproterenol for 5 minutes.  Cells were 
rinsed in PBS, and then harvested and lysed in 0.5ml of HSE buffer containing protease 
inhibitors plus phosphatase inhibitors (10uM sodium pyrophosphate, 50uM sodium 
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fluoride).  Supernatants were incubated with 4ug of antibody and 20ul of protein G-
agarose beads.  Bound proteins were analyzed by immunoblotting. 
 For immunoprecipitations from rat heart, extract was prepared as described above.  
Proteins were immunoprecitated from 1ml of extract using specific antibodies bound to 
protein G-agarose.  After extensive washing with HSE buffer, the associated proteins 
were determined by immunoblot.  
2.4.4. Phosphatase Assay  
Phosphatase activity was measured as previously described using 32P-labeled 
histone as a substrate (144).  Histone was radiolabeled in a reaction containing 250mM 
MOPS (pH 7.4), 2.5mM MgAc, 100mM beta-mercaptoethanol, purified PKA catalytic 
subunit, 1mM ATP, 20mM histone and 1mCi [gamma-32P-ATP (6000 Ci/mmol)]. The 
reaction was terminated by the addition of 50% TCA and [32P]-histone was purified from 
free radionucleotide by centrifugation.  After repeated washing, the [32P]-histone was 
suspended in 200ul of PP2A buffer (25mM Tris, [ph 7.4], 1mM DTT, and 10mM 
MgCl2). 
 To measure phosphatase activity, immunoprecipitated complexes were washed 
twice in HSE buffer and again in PP2A buffer.  The immunoprecipitates were incubated 
for 30 minutes at 30°C in 20ul of PP2A buffer containing 100,000 cpm of [32P]-histone in 
the presence and absence of inhibitors.  Reactions were terminated by the addition of 
100ul of 20% TCA followed by 10 min centrifugation.  TCA supernatants containing 
released 32P04 were measured using a scintillation counter. 
  45 
  
 
2.4.5. PKA activity assay 
PKA activity was measured according to the method of Corbin and Reimann (145). 
Immunoprecipitated complexes were washed twice in HSE buffer and once in PKA assay 
buffer (50mM Tris, pH 7.5 and 5mM MgCl2).  The beads were then incubated in assay 
buffer containing 30uM Kemptide 100uM ATP, 5uM γP32-ATP and 3uM cAMP.  After 
incubating the samples at 30°C for 30 minutes, the reaction mixture was spotted onto 
phosphocellulose strips and washed five times in 75mM phosphoric acid and once in 
95% ethanol.  Filters were air dried and counted. 
2.4.6. Detection of I-1 phosphorylation 
For I-1 phosphorylation experiments, 24 hours post transfection, cells were 
stimulated with 1uM Isoproterenol for 5 minutes.  Cells were rinsed in PBS and scraped 
into 0.5 ml of HSE buffer containing protease and phosphatase inhibitors (10mM sodium 
pyrophosphate, 50mM sodium fluoride).  After centrifugation for 10 minutes at 13,000g, 
the clarified supernatant was added to 1ml of isopropanol, and total cellular protein was 
precipitated by incubation at -20°C for 2 hours followed by centrifugation at 13,000g for 
30 minutes.  Precipitated proteins were resuspended in 200ul of 2X SDS-PAGE sample 
buffer (0.5M Tris-HCl, [pH 6.8], 1% glycerol, 10% SDS, and 0.5% beta-
mercaptoethanol) that was added to the cellular pellet.  For immunoblot analysis using a 
phospho-specific antibody, 20ul of each isolated sample was subjected to SDS-PAGE.  
For in vitro I-1 phosphorylation GST-fusion proteins were incubated with cellular 
extracts isolated from transfected HEK293 cells as described above.  After an overnight 
incubation and washing of the beads with HSE buffer lacking EDTA, the complex was 
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incubated in 25ul of PKA assay buffer (25mM Tris [pH 7.4], 1mM DTT, 10mM MgCl2, 
1mM ATP, and 3mM cAMP) for 30 minutes at 37°C.  The bound proteins were then 
subjected to immunoblot analysis. 
 
2.5. RESULTS 
2.5.1. AKAP18 associates with Inhibitor-1 in vivo 
The formation of signaling complexes by AKAPs that include PKA and individual 
PKA substrates contributes to the efficiency and fidelity of cAMP signal transduction 
(42).  As I-1 is an important PKA target, we considered I-1 might associate with 
anchored PKA in the heart.  To test this idea, we isolated PKA-AKAP complexes from 
rat heart extract by affinity chromatography using Rp-cAMPs-agarose that binds the PKA 
regulatory subunits.  This compound is a competitive inhibitor of PKA, so it does not 
stimulate activation of the kinase, thus leaving the holoenzyme intact.    I-1 was 
consistently detected in the Rp-cAMPs pulldowns, but not under conditions which excess 
cAMP was added to the extracts to block specific binding to the beads (Figure 2.1A). As 
a control, both the PKA regulatory subunit type I, type II, as well as the PKA catalytic 
subunit were found specifically in cAMP-agarose pulldowns. To confirm that the PKA 
holoenzyme containing the catalytic subunit associated with I-1, we used GST-tagged, 
purified I-1 to pulldown PKA from rat heart extract. As shown in Figure 2.1B, kinase  
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Figure 2.1: Inhibitor-1 associates with PKA in heart cells.  
A. Rat heart extracts were incubated with Rp-cAMPs-agarose in the presence or absence 
of excess cAMP (50uM).  I-1 in whole extract (Ex, 2% of total) and the cAMP-associated 
fraction of I-1, PKA-RI, PKA-RII, and PKA-catalytic subunit were determined by 
immunoblotting. n=3. B.  Rat heart extract was incubated with either GST-I-1 (3µg) or 
control GST protein, and the bound proteins were assayed for PKA activity using 
Kemptide as a substrate. n=3, *p<0.008, **P<0.01. C. PKA-RI, PKA-RII, and PKA-
catalytic subunit present in GST control and GST-I-1 pulldowns were detected by 
immunoblot.  Extract is 5% of the total protein used for each pulldown. 
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activity was found specifically in GST-I-1 complexes, and not with GST alone.  Kinase 
activity was specific for PKA, as the addition of the PKA specific inhibitor PKI inhibited 
PKA activity in the pulldowns.  Furthermore, PKA catalytic subunit as well as PKA 
regulatory type I and type II subunits were found in GST-I-1 pulldowns from rat heart 
extract.  Importantly, the percentage of PKA-RII was enriched 20 fold over RI, 
suggesting this AKAP is a primarily RII binding AKAP (Figure 2.1C).  In summary, 
these data show that I-1 associates with a PKA complex in the heart.   
Next we sought to identify which AKAP might mediate this interaction between 
PKA and Inhibitor-1 in the heart.  To do this, we isolated proteins in rat heart extracts 
that associated with I-1 using GST-tagged Inhibitor-1 protein, and then blotted for some 
highly characterized AKAPs found in the heart.  As shown in Figure 2.2A, a high 
molecular weight AKAP18 isoform was readily detected in GST-I-1 complexes, in 
addition to what are potentially lower molecular weight AKAP18 isoforms that were less 
prevalent.  As a control, I-1 did not associate with mAKAP, another muscle enriched 
AKAP involved in the induction of cardiac hypertrophy (Supplementary Figure 2.1) 
(144).  The molecular weight of the intense, 45kDa band implied that the major isoform 
pulled down by GST-I-1 was either AKAP18δ or AKAP18γ.  Importantly, this 
interaction was not observed using GST alone, demonstrating the specificity of the 
interaction. The association of AKAP18 with I-1 was confirmed using an I-1 antibody to 
immunoprecipitate the scaffold from HEK293 cells expressing GFP-tagged AKAP18γ 
and I-1 (Figure 2.2B).  Additionally, complexes containing PKA were purified from the 
HEK293 cell extracts using Rp-cAMPs agarose.  I-1 co-purified with the agarose only 
when co-expressed with the anchoring protein, mimicking the results found with the 
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Figure 2.2:  AKAP18 associates with I-1 A. Isolated rat heart extract was incubated 
with either GST-I-1 or control GST-protein.   
AKAP18 was detected by western blot (left) and total protein by Ponceau stain (right) 
n=3. B. HEK293 cells expressing GFP-AKAP18γ in the presence and absence of I-1 
were used for immunoprecipitations with an I-1 antibody, and AKAP18γ association was 
determined by immunoblot using a GFP antibody. C. HEK293 cells were transfected with 
Inhibitor-1 in the presence and absence of GFP-tagged AKAP18γ.  Isolated extracts were 
incubated with cAMP agarose and immunoblotting demonstrated association of I-1. 
Immunoblots of whole cell extracts (2.5% of total) are shown as controls for both B and 
C. n=3 for all panels. 
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 endogenously expressed I-1 and AKAP18 in the heart (Figure 2.2C).  Together, these 
data suggest that AKAP18, I-1, and PKA form a multi-molecular signaling complex in 
the heart as well as when expressed in heterologous HEK293 cells. 
2.5.2. I-1 Directly Binds a Long Isoform of AKAP18 
AKAP18γ is one of the larger protein isoforms encoded by the alternatively spliced 
AKAP18 gene (schematic shown in Figure 2.3A).  The smaller AKAP18α is N-terminally 
myristoylated and palmitoylated, allowing for attachment to the plasma membrane where 
it facilitates PKA phosphorylation of the L-type calcium channel (129). In contrast, the 
large isoforms of AKAP18 are targeted to the sarcoplasmic reticulum where they from a 
signaling complex with phospholamban (134).  In order to define which isoform of 
AKAP18 is the primary target for I-1 binding, we performed pulldown assays using 
bacterially expressed GST-tagged I-1 with these two isoforms of AKAP18. GST-I-1 
incubated with either bacterially expressed, S-tagged AKAP18α or AKAP18γ was 
subjected to S-tag pulldown assay.  GST-I-1 was found in the S-protein agarose only in 
the presence of the larger isoform AKAP18γ (Figure 2.3B).  Importantly, these data also 
demonstrate that I-1 and the scaffolding protein can bind directly in a purified system.    
2.5.3. Expression of AKAP18 enhances I-1 phosphorylation on Threonine 35 
The role of an AKAP is to anchor the kinase in close proximity to its target in order 
to enhance PKA phosphorylation (42).  Therefore, AKAP18 should enhance PKA-
mediated phosphorylation of I-1 by assembling a signaling complex containing both I-1 
and PKA.  To test whether PKA binding to AKAP18 is important for I-1 
phosphorylation, we first confirmed that a ternary complex consisting of AKAP18, PKA 
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Figure 2.3: Direct binding of AKAP18g and Inhibitor-1.   
A.  Schematic diagram depicting the known AKAP18 splice variants.  PLN, 
phospholamban; LTCC, L-type calcium channel.  B. GST-I-1 fusion protein (3µg) was 
incubated with S-tagged AKAP18α or S-tagged AKAP18γ fusion protein (3µg), or S-
protein agarose alone.  S-tagged pulldown assays were performed and association of 
GST-I-1 was determined by western blot.  Total protein was detected by Ponceau stain.  
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 and I-1 could be isolated from transfected HEK293 cells.  Cell extracts were prepared 
from HEK293 cells expressing AKAP18γ or a C-terminal truncated AKAP18γ mutant 
lacking the PKA binding site (AKAP18γ 1-268).  GST-I-1 was incubated with the 
isolated cell extracts, and PKA activity assays were performed on the pulldowns (Figure 
2.4A).   While I-1 bound both full length AKAP18γ and AKAP18γ 1-268 (Figure 2.4B, 
top panel), kinase activity was only detected with full length AKAP18γ (Figure 2.4A).   
Kinase activity was blocked by the addition of PKI, demonstrating the specificity of the 
reaction to measure PKA activity assay.  In support of this finding, PKA-RII was not 
detected in GST-I-1 pulldowns from cells expressing AKAP18γ 1-268 (Figure 2.4B, 
middle panel, GST-protein stain shown in Supplementary Figure 2.2A).  These data show 
that AKAP18γ can serve to couple PKA to I-1 in a heterologous system.    
Next, we determined if the associated kinase could phosphorylate I-1 at Thr-35.  
Consistent with the results of the PKA activity assays, cAMP-dependent phosphorylation 
of I-1 was greatly enhanced in GST-I-1 pulldowns containing full-length AKAP18γ 
compared to those containing the AKAP18γ PKA-binding mutant (Figure 2.4C).  In order 
to show that AKAP18 enhances the PKA phosphorylation of I-1 in response to G-protein 
coupled receptor stimulation, the AKAP18γ proteins were co-expressed with I-1 in 
HEK293 cells.  In the absence of stimulation, no I-1 phosphorylation was detected using 
the phospho-specific antibody.  However, β-adrenergic stimulation with 1uM 
isoproterenol for 5 minutes rapidly enhanced I-1 phosphorylation when AKAP18γ was 
co-expressed (Figure 2.4D) in a PKA dependent manner (Supplementary Figure 2.2B). 
Importantly, this stimulated increase was significantly attenuated in cells transfected with 
I-1 and AKAP18γ lacking the PKA binding domain (42±5.7% of wildtype, Figure 2.4E).  
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Figure 2.4: AKAP18 orchestrates I-1 phosphorylation by linking PKA with the 
Inhibitor.  
A. GST-I-1 fusion protein (3ug) was incubated with HEK293 cell lysate extracted from 
prepared from cells expressing AKAP18γ, or AKAP18γ 1-268.  PKA activity was 
determined in each GST pulldown in the presence and absence of 50nM PKI.  B.  
Pulldowns were performed as described in A and the association of the AKAP, as well as 
PKA-RII with GST-I-1 was demonstrated by immunoblot.  C. GST-I-1 fusion protein 
(3ug) was incubated with HEK293 cell lysate as prepared in A, and PKA associated with 
the GST pulldowns was activated by the addition of cAMP. I-1 phosphorylation was 
detected by western blot using an antibody that specifically recognized the inhibitor when 
phosphorylated at Thr-35 (upper panel).  Total I-1 in each pulldown is shown in the 
middle panel while protein expression of the different AKAP18 constructs is shown in 
the bottom panel.  D.  HEK293 cells expressing I-1 and either full-length AKAP18γ or 
AKAP18γ 1-268 were stimulated with 1mM Isoproterenol for 5 minutes.  Whole cell 
lysate were analyzed by western blot using antibodies against phospho-I-1 Thr-35 (upper 
panel), I-1 (middle panel) and GFP for the AKAP18 constructs (lower panel).  E.  
Densitometric quantification of I-1 phosphorylation shown in C normalized to 
isoproterenol, AKAP18γ sample. n=3 for each panel, *p<0.05. 
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Together, these data show that targeting of PKA to I-1 via the association with AKAP18 
facilitates I-1 phosphorylation by the kinase.   
2.5.4. AKAP18 bind PP1 in vivo   
Because AKAPs often serve as scaffolds for multi-molecular signaling complexes 
that include both kinase and phosphatases, we considered that the I-1 target PP1 might 
also be present in AKAP18γ complexes.  To test this hypothesis, protein complexes were 
immunoprecipitated from rat heart extract using an antibody that recognizes the catalytic 
subunit of PP1 (Figure 2.5A).  A high molecular weight isoform of AKAP18 co-
precipitated with the PP1 antibody, but not with IgG control, implying that PP1 and 
AKAP18γ and/or AKAP18δ associate in vivo.  In reciprocal experiments, STREP-tagged 
AKAP18γ was used to pulldown PP1 from rat heart extract (Figure 2.5B).  PP1 did not 
associate with STREP-beads alone, demonstrating the specificity of this interaction.  
Furthermore, an okadaic acid-sensitive phosphatase activity was found in AKAP18 
immunoprecipitates isolated from rat heart extract (Figure 2.5C). Taken together, these 
data show that PP1 and AKAP18 form a complex in the rat heart.   
 Next, we confirmed the PP1/AKAP18γ complexes could be reconstituted in 
transfected HEK293 cells.  In support of our findings that PP1 and AKAP18 formed a 
complex in rat heart cell extract, PP1 also associated with AKAP18γ in transfected 
HEK293 cells (Figure 2.5D).  Importantly, this association was lost when cells not 
expressing the anchoring protein were immunoprecipitated with the AKAP18 antibody, 
demonstrating the specificity of the interaction.  Importantly, we were unable to 
immunoprecipitate the scaffold with a PP2A catalytic subunit antibody (Figure 2.5E), 
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Figure 2.5:  AKAP18 is a PP1 anchoring protein  
A. Protein complexes were immunoprecipitated from rat heart extract with either an 
antibody specific to PP1 catalytic subunit or control IgG and detected using an AKAP18 
antibody.  Extract represents 2.5% of total input.  B. Rat heart extracts were incubated 
with either STREP-tagged (ST) AKAP18γ fusion protein or control STREP protein.  PP1 
in the pulldowns and total extract (2.5% of total input) were detected with an antibody to 
PP1 catalytic subunit. C. Protein complexes were immunoprecipitated from rat heart 
extract with either an antibody specific to AKAP18 or control IgG and assayed for 
phosphatase activity in the presence or absence of okadaic acid (100nM).  Amount of 
PP1 in each group is demonstrated by western blot analysis of the immunoprecipitate.  D. 
Protein complexes were immunoprecipitated from lysates prepared from control HEK293 
cells or cells expressing GFP-tagged AKAP18γ using an AKAP18 antibody.  Precipitated 
PP1 was detected using a catalytic subunit antibody.  E.  Protein complexes were 
immunoprecipitated from lysates prepared from HEK293 cells expressing GFP-tagged 
AKAP18γ using either a PP1 or PP2A catalytic subunit antibody (designated as PP: 
Protein Phosphatase).  AKAP18 in the immunoprecipitates and AKAP18, PP1 and PP2A 
in the total extract (2.5% of total) were detected by immunoblot. n=3 for all panels.
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even though phosphatase activity was found in both PP2A and PP1 
immunoprecipitations, (Supplementary Figure 2.2), suggesting that under these 
conditions, AKAP18γ selectively binds PP1.  Taken together, our data demonstrate a 
complex consisting of AKAP18 and PP1 that can be isolated from both rat heart extract 
as well as from transfected HEK293 cells. 
 
2.5.5. AKAP18 is the scaffold for a PKA, PP1 and I-1 signaling complex 
The data presented here suggest that I-1, PKA and PP1 all associate with AKAP18 
in both transfected cells and heart extract.  One important implication of these data is that 
the anchoring protein may sequester these enzymes into the same signaling complex, and 
that compartmentation is dependent on AKAP18.  To test this hypothesis, we investigated 
the importance of AKAP18γ expression for formation of the complex.  HEK293 cells 
were transfected with I-1 in the presence and absence of AKAP18γ, while endogenous 
PP1 catalytic and PKA regulatory subunit were used for these experiments.  Each protein 
was immunoprecipitated, and association of the other three proteins was determined by 
western blot.  As shown in Figure 2.6, the expression of AKAP18γ was required for the 
association of the PKA-RII with I-1 and PP1, as well as association of PP1 to both 
AKAP18γ and the PKA-RII.  Furthermore, I-1 was only found in PKA -RII 
immunocomplexes upon expression of AKAP18γ.  While, I-1 and PP1 can associate in 
the absence of AKAP18γ, co-expression of the anchoring protein significantly increased 
the association of the two proteins. Controls demonstrating the specificity of each 
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Figure 2.6:  AKAP18 sequesters PKA, PP1 and I-1 to a specific signaling complex.  
Protein complexes were immunoprecipitated from lysates prepared from HEK293 cells 
transfected with I-1 plus and minus GFP-AKAP18g using antibodies to AKAP18, I-1, 
PP1 and PKA-RII.  Proteins in the extracts (bottom panels) and immunoprecipitates (top 
panels) were detected with the respective antibodies.  Total protein (5% of input) is 
shown below. n=3 for each. 
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immunoprecipitation are shown in Supplementary Figure 2.4. The data presented in 
Figure 6 effectively argues the importance of AKAP18 for linking PKA to I-1 and PP1. 
 
2.5.6. AKAP18 orchestrates the PKA-mediated inhibition of PP1 activity  
Phosphorylation of I-1 by PKA induces potent inhibition of PP1 activity (91).  Our 
data suggest AKAP18-bound PKA facilitates this phosphorylation, and hence, should 
enhance the ability of I-1 to inhibit the phosphatase.  To study this potential functional 
consequence of AKAP18 complex formation, we first isolated AKAP18 complexes from 
rat heart extract, and determined the effect of cAMP on the associated endogenous PP1 
activity.  Activation of PKA in the complex by the addition of 3uM cAMP inhibited PP1 
activity (95±4.67%) present in the AKAP18 immunoprecipitates (Figure 2.7A).  This 
inhibition was attributed to the activation of PKA, as inhibition was reversed by inclusion 
of the PKA inhibitor PKI (50nM).  These data demonstrate that the PKA-stimulated 
inhibition of AKAP18-bound PP1 is functional in native AKAP18 complexes isolated 
from rat heart.  
 Showing the necessity of PKA anchoring to AKAP18 for PP1 inhibition extended 
these results.  HEK293 cells were transfected with I-1 and either full-length AKAP18γ or 
the AKAP18γ PKA binding mutant.  After stimulation with 1uM isoproterenol for 5 
minutes, complexes were isolated using an antibody that recognizes the anchoring 
protein, and the associated phosphatase activity was measured.  As shown in Figure 2.7B, 
PKA anchoring to the complex was required for effective inhibition of the associated  
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Figure 2.7: PKA binding to AKAP18 is necessary for PKA-induced inhibition of 
PP1.  
A. Protein complexes were immunoprecipitated from rat heart extract with either an 
antibody specific to AKAP18 or control IgG and assayed for phosphatase activity in the 
presence and absence of CPT-cAMP (3uM) or PKI (50nM) B.  Phosphatase activity 
associated with protein complexes immunoprecipitated using an antibody specific for 
myc-tag from lysates prepared from HEK293 cells expressing I-1 and either myc-tagged 
full-length AKAP18γ or AKAP18γ 1-268 was assayed.  Endogenous PP1 was used. Cells 
were stimulated with 1uM isoproterenol for 5 minutes as indicated.  AKAP18 proteins in 
the total lysates were detected with a myc antibody.  n=3 for each panel, *p<0.05.  C.  
Cell lysates were prepared as in B.  PP1 immunocomplexes were isolated and association 
of AKAP18 and I-1 was determined by western blot.  n=3 for each.  
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phosphatase activity, as the cAMP-induced inhibition of PP1 was lost when AKAP18 
could not bind PKA.  This result is not due to a loss of complex formation, as similar 
amounts of AKAP18 and I-1 were found in PP1 immunocomplexes (Figure 2.7C). Taken 
together, these data show that the binding of I-1, PP1 and PKA by AKAP18 permits the 
efficient regulation of PP1 activity by cAMP signaling in cells. 
 
2.6. DISCUSSION 
In this report, we identify the first interaction between Inhibitor-1 and an A-kinase 
anchoring protein, AKAP18.  Functional AKAP18 complexes containing I-1, the target 
PP1, and PKA were isolated from both rat heart extract and transfected HEK293 cells. 
The functional significance of these interactions was demonstrated in two ways.  First, 
complex formation facilitated the cellular phosphorylation of I-1, as disruption of PKA 
association with AKAP18 significantly decreased phosphorylation of I-1 at Thr-35.   
Second, PKA binding to AKAP18 was required for isoproterenol-induced inhibition of 
the associated PP1 activity.  This information establishes AKAP18 as a regulator of both 
I-1 and PP1 activity and advances our understanding of phosphatase regulation. 
PKA phosphorylation of I-1 at Thr-35 and the resulting inhibition of PP1 activity 
acts as a feed-forward mechanism to enhance PKA phosphorylation of downstream 
effectors that would otherwise be dephosphorylated by PP1 (123, 140).  PKA anchoring 
to AKAP18 is now shown to play an integral role in this process, since disruption of PKA 
anchoring to AKAP18 prevented cAMP-mediated inhibition of the PP1 activity 
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associated with the complex.  As a result, in cells such as cardiac myocytes that express 
AKAP18γ and AKAP18δ, these complexes should be highly sensitive to cAMP signals.  
Previous work has demonstrated the existence of multi-protein complexes 
containing I-1 and PP1.  An I-1/PP1 complex mediated by interactions with the Growth 
arrest and DNA damage protein 34 (GADD34) was found in active squirrel brains (146). 
GADD34 was shown to enhance the I-1-mediated inhibition of PP1 in order to regulate 
the phosphorylation of the transcription factor eIF-2a.  While GADD34 is found in the 
heart, the role of this complex in the regulation of PP1 in this tissue is unknown (147).  
An important difference between GADD34 and AKAP18 in the regulation of PP1 
activity is that the AKAP also anchors PKA to the complex, enhancing I-1 
phosphorylation.  Thus, the ability of AKAP18 to sequester I-1 and PKA ensures spatial-
temporal control of I-1 phosphorylation. 
  Several AKAPs have been previously implicated to bind to and regulate 
phosphatase activity.  For example, the direct association between AKAP220 and PP1 
inhibits phosphatase activity (100).  Additionally, mAKAP binds to PP2A and mediates a 
cAMP-induced increase of phosphatase activity through PKA phosphorylation of PP2A-
B56d subunit (144).   In contrast to these other complexes, PP1 bound to AKAP18 is 
active, and PKA phosphorylation of the phosphatase’s regulator results in its inhibition.  
To date, this is the first identification of an AKAP-mediated regulation of I-1 
phosphorylation.  
In the heart, I-1 activity is spatially restricted and selectively regulates PP1 
activity at the sarcoplasmic reticulum, where PP1 opposes phospholamban 
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phosphorylation (123, 140).   In contrast to the smaller isoforms of AKAP18 (α and β) 
that are targeted to the plasma membrane, the long isoforms (γ and δ) bind directly to 
phospholamban, facilitating PKA phosphorylation of phospholamban (134).  Our results 
imply that AKAP18 may facilitate the localization of I-1 to the sarcoplasmic reticulum, 
further promoting phospholamban phosphorylation.  Future investigations in our 
laboratory will address how the intracellular targeting of I-1 by the long isoforms of 
AKAP18 affects the kinetics and sensitivity of phospholamban phosphorylation. 
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2.7. SUPPLEMENTARY FIGURES  
 
 
Supplementary Figure 2.1:  
Isolated rat heart extract was incubated with either GST-I-1 or control GST-protein.  
mAKAP was detected by western blot (left) and total protein by Ponceau stain (right) 
n=3.  
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Supplementary Figure 2.2:  
A. GST-I-1 fusion protein (3ug) was incubated with HEK293 cell lysate prepared from 
cells expressing AKAP18γ, or AKAP18γ 1-268.  Protein stain corresponds to western 
blots shown in Figure 4B.  B. HEK293 cells expressing I-1 and full-length AKAP18γ 
were stimulated with 1uM Isoproterenol for 5 minutes after a one hour preincubation 
with H-89 (10uM).  Whole cell lysate were analyzed by western blot using antibodies 
against phospho-I-1 Thr-35 (upper panel), I-1 (middle panel) and GFP for AKAP18 
(lower panel). 
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Supplementary Figure 2.3:  
Protein complexes were immunoprecipitated from lysates prepared from HEK-293 cells 
expressing GFP-tagged AKAP18γ using either a PP1 or PP2A catalytic subunit antibody. 
Phosphatase activity in the immunoprecipitates was performed as described in the 
methods section. Immunoprecipitations correspond to western blots shown in Figure 5E. 
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Supplementary Figure 2.4:  
Protein complexes were immunoprecipitated from lysates prepared from HEK293 cells 
transfected with I-1 plus and minus GFP-AKAP18γ using antibodies to AKAP18, 
PKARII and PP1. A). AKAP18 was immunoprecipitated using an antibody specific for 
the anchoring protein followed by western blot analysis using an antibody that recognized 
the GFP tag on AKAP18. Proteins in the extracts are shown in the bottom panels. B). 
The regulatory subunit of PKA was immunoprecipitated and PKA activity was 
determined on the immunoprecipitate, demonstrating equal amounts of PKA was 
immunoprecipitated under each condition. Total protein in the extracts is shown in the 
bottom panels. C) Phosphatase assay performed on PP1 immunoprecipitates in the 
presence and absence of AKAP18. Similar amounts of phosphatase were 
immunoprecipitated under each condition. Total protein in the extracts is shown in the 
bottom panel. Total protein is 5% of input. n=3 for each.
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3.1. 	  ABSTRACT 
 
A-kinase anchoring proteins constitute a family of scaffolding proteins that 
contribute to the spatial temporal regulation of phosphorylation events mediated by the 
cAMP-dependent protein kinase A (PKA).  In particular, AKAP18 is a family of 
alternatively spliced proteins that participates in cardiac calcium dynamics.  Here, we 
demonstrate that AKAP18γ can oligomerize, as demonstrated by immunoprecipitation 
from transfected HEK293 cells and by direct protein-protein association.  This appears to 
be an isoform specific phenomenon, as AKAP18α did not form homo-oligomers with 
itself or hetero oligomers with AKAP18γ. Surface plasmon resonance analysis suggests 
two sites of interactions between AKAP18γ and itself, with each site displaying high 
binding affinity and KD values in the nanomolar range.   This raised the possibility of the 
existence of larger order complexes.  Indeed, photon counting histogram (PCH) and 
Numbers and Brightness analysis of AKAP18γ -EGFP expressed in Vero cells showed 
that AKAP18γ -EGFP are found in vivo as monomers, dimers, trimers and larger 
oligomers, with AKAP18γ dimers and trimers constituting the predominant isoforms. The 
functional significance of AKAP18γ oligomerization is to enhance substrate 
phosphorylation, as predicted by computational modeling of AKAP18γ -bound PKA 
dynamics in response to cAMP stimulation in a specific cell compartment.  In conclusion, 
our study reveals that oligomerization of AKAP18γ is an important step in mediating 
effective substrate phosphorylation in cellular microdomains. 
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3.2. 	  INTRODUCTION 
 
Phosphorylation of target proteins is one of the key underlying mechanisms utilized 
by the cell to induce changes in physiology and function.  Although much work has 
previously defined multiple kinase-substrate interactions, how specificity of these 
phosphorylation events is achieved is still under investigation.  Recent work has 
suggested that the subcellular localization of signaling enzymes to discrete locations in 
the cell confers spatial temporal control over phosphorylation events (4, 148).  This is 
facilitated by a category of scaffolding proteins, which tether the kinase to the same 
signaling complex as its substrates, allowing for increased speed and amplification of 
phosphorylation events (148, 149). While the physiological significance of many kinase 
binding scaffolds has been investigated, how their complex molecular architecture 
influences cellular processes is presently unclear. 
An important mechanism for the transduction of cellular events is oligomer 
formation of signaling enzymes (150, 151). Whether occurring as a hetero or homo 
oligomer, this process often begins at the level of the receptor as a first step in 
transducing a signal from outside the cell to the intracellular environment (152, 153). 
However, oligomer formation is not limited to upstream signaling events. A few recent 
studies have demonstrated that scaffolding proteins can oligomerize, influencing their 
signaling functions (154).  For example, the yeast scaffold Ste5, which initiates the 
mitogen-activated protein (MAP) kinase cascade in the Saccharomyces cerevisiae 
pheromone response pathway, dimerizes upon pheromone treatment, to enhance MAP 
kinase signaling in the cell (155, 156). Similary, oligomerization of β-arrestin 1 keeps the 
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scaffold cytoplasmic, inhibiting its nuclear actions (154). Importantly, these examples 
demonstrate that oligomerization greatly impacts the function of the scaffold. 
For cAMP signaling, A-kinase anchoring proteins (AKAPs) focus the actions of 
the cAMP-dependent protein kinase (PKA) to specific targets, allowing for 
microdomains of kinase activity (43, 149). Additionally, it is becoming more evident that 
AKAPs have a more profound effect on the regulation of substrate phosphorylation than 
just binding PKA. The concept of holistic substrate phosphorylation (i.e. conditions in 
which substrate phosphorylation is promoted followed by dephosphorylation) regulation 
by AKAPs is backed by the finding that AKAPs can bind to Phosphodiesteraes, Protein 
Phosphatases, and Adenyl Cyclases as well, allowing for localized fluctuations in cAMP 
concentrations (101, 157-160).   
Our recent investigations focused on defining AKAP18-orchestrated cAMP 
microdomains.   AKAP18 is a family of alternatively spliced isoforms that are known to 
play a role in cardiac calcium dynamics (129, 134, 161).  Here, we reveal that AKAP18γ 
oligomerizes, as demonstrated both in vitro and in a cellular context, resulting in an 
enhancement of substrate phosphorylation. This self interaction is limited to the large 
isoforms of AKAP18, correlating with previous findings that AKAP18α and AKAP18γ 
are differentially targeted in the cell and display unique functions (131).  In agreement 
with this finding, surface plasmon resonance analysis finds that AKAP18γ specifically 
interacts with itself and displays a low nano-molar binding affinity.  Using Fluorescence 
Correlation Microscopy and Numbers and Brightness analysis, we demonstrate that 
AKAP18γ forms stable, higher order complexes in cells, with concurrent existence of 
monomers, dimers and trimers present.  In order to understand the functional significance 
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of oligomerization in the context of substrate phosphorylation, we developed a 
mathematical model using the Virtual Cell Software.  Computational analysis suggests 
that formation of higher order structures enhances the magnitude of substrate 
phosphorylation associated with AKAP complexes.    Collectively, our work 
demonstrates that oligomerization of AKAP18 impacts phosphorylation events 
orchestrated by the AKAP and suggests these findings may be applied to other AKAP 
complexes. 
 
3.3. EXPERIMENTAL METHODS 
3.3.1. Antibodies 
For western blot analyses, the following antibodies were used: mouse monoclonal 
GFP (Santa Cruz, 1:1000), goat polyclonal dsRED (Santa Cruz, 1:1000), rabbit His tag 
(Millipore, 1:10,000), and mouse GST tag (Santa Cruz, 1:10,000).  
3.3.2. Construct design   
AKAP18γ-pET32a, AKAP18γ-EGFP-N1 and AKAP18α-EGFP-N1 were used as 
previously described (129, 131, 162). AKAP18γ 1-150-EGFP and AKAP18γ 150-end-
EGFP were constructed by PCR amplification and sub-cloning into the EcoRI-BamHI 
sites of pEGFP-N1 (Clontech). AKAP18γ-pMAL was constructed by PCR amplification 
and sub-cloning into the BamHI-EcoRI sites of pMal-c5E (NEB).  Deletion constructs 
were made by site-directed mutagenesis, placing stop codons in the appropriate 
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sequences.  AKAP18γ-mCherry was constructed by PCR amplification and sub-cloning 
into the EcoRI-BamHI sites of pmCherry-C1 (Clontech). 
3.3.3. Recombinant Protein Purification   
For purification of recombinant AKAP18γ-His/S-tag, bacteria were grown to OD595 
0.8 then induced with IPTG (1mM final concentration) for 3hrs. After centrifugation, the 
bacteria were lysed in binding buffer (20mM HEPES (pH 7.4), 0.5M NaCl, 5mM 
Imidazole along with 0.5% triton-X, 0.25mg/ml lysozyme, 1mM DTT, 1mM EDTA, and 
Protease Inhibitor Cocktail) for 2hrs. Supernatant was collected by centrifugation and 
protein purified by Ni-agarose pulldown overnight (0.5mL of 50% slurry; Ni-NTA 
solution, Qiagen). Ni-agarose was washed 3X in binding buffer and protein was eluted 
with binding buffer + 800mM Imidizole. Protein was concentrated with Amicon Ultra 
centrifugal filters (Millipore). Elution buffer was slowly exchanged with PBS while 
concentrating the protein in the centrifugal tubes. Protein quality and concentration was 
confirmed by running the protein on SDS-PAGE gel with BSA standards and staining 
with coommasie brilliant blue. The gel was scanned post staining to calculate the exact 
protein concentration using Image J software (NIH).  
A similar protocol was followed for AKAP18γ-maltose binding protein (MBP) 
purification.  The maltose binding protein tagged protein was lysed in buffer containing 
Protease Inhibitor Cocktail, 20mM Tris-HCl (pH 7.4), 200mM NaCl, 1mM each of 
EDTA, Na Azide, and DTT. Separated cell lysate was passed through Amylose resin 
packed column, followed by 5 washes with lysis buffer. The protein was eluted using 
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lysis buffer containing 10mM maltose.  The protein was concentrated and analyzed as 
described above.  
3.3.4. Cell transfection 
For analysis of AKAP18γ binding to itself, HEK-293 cells at 50% confluency were 
transfected using calcium phosphate precipitation with pEGFP-AKAP18γ and either 
pmCherry-AKAP18γ or pmCherry control (10ug) overnight under 5% CO2 at 37°C.  
Cells were harvested 18hrs later for cell extract. 
 Vero cells were used for all confocal studies. Briefly, 35mm dishes of Vero cells 
at ~70% confluency were transfected with 2ug plasmid DNA (pEGFP or AKAP18γ-
EGFP) in Opti-MEM (Invitrogen) serum free medium using 6ul PLUS reagent and 6ul 
lipofectamine. Cells were used for photon counting histogram analysis or number and 
brightness analysis 5-10hrs post transfection to achieve low yet detectable levels of the 
expressed protein construct. 
3.3.5. Pulldown Assays 
In-vitro: Purified His/S tagged AKAP18γ (5ug) was incubated with either 
AKAP18γ-MBP) (5ug) or expressed MBP, and rocked overnight at 4°C. The next day, 
the Amylose resin was added for 4hrs to isolate the complex.  The Amylose beads were 
washed 4X in lysis buffer (as described in maltose tagged protein purification above) for 
10-15mins while rocking.  The complex was then subjected to SDS-PAGE purification 
followed by western blot analysis. 
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From cell supernatant:  Lysates prepared from AKAP18γ-EGFP transfected HEK 
293 cells were incubated with either 5ug purified recombinant AKAP18α-His/S-tag pre-
loaded on S-Agarose beads (Novagen), or with purified 5ug AKAP18γ-MBP pre-loaded 
on Amylose Agarose beads (Novagen).  For control groups, either unrelated His/S tag 
protein or isolated MBP was used.  The pulldowns were rocked overnight at 4°C, 
followed by 4 washes with their respective buffers for 10-15min while rocking. The 
isolated complex was then subjected to SDS-PAGE purification followed by western blot 
analysis.  
3.3.6. SPR Analysis 
SPR analysis was performed using a BIAcore T100.  Either purified recombinant 
AKAP18γ or AKAP18α were covalently immobilized using NHS (N-
hydroxysuccinamide) and EDC [1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide] 
(Biacore amine coupling kit) to the surface of a sensor chip (BIAcore type CM5).  The 
amount of ligand bound (in resonance units RUs) was 150RU.  Protein analytes 
(AKAP18γ or AKAP18α) were diluted at increasing concentrations (12.5-200nM) in 
HBS buffer (10mM Hepes (pH 7.4), 150mM NaCl and 0.005% Surfactant P20) and were 
injected over the sensor surface at a flow rate of 30ul/min for 300s.  Post injection phase, 
dissociation was monitored in HBS buffer for 300s at the same flow rate.  The surface 
was regenerated between injections using 10mM NaCl at a flow rate of 50ul/min for 30s.  
Obtained sensograms were all processed by BIAcore T100 evaluation software. 
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3.3.7. Photon Counting Histogram Analysis 
Photon counting of EGFP in solution and AKAP18γ-EGFP in live Vero cells was 
performed with a Zeiss LSM 510 ConFocor3 confocal microscope mounted on an 
AxioVert 200M. Excitation was achieved at 488nm with a 30mW Argon laser at 0.5% 
power. Fluorescence emission was collected with a 40X water immersion objective 
(Zeiss C-Apochromat 1.2W Korr UV-Vis-IR). Detection was performed with an 
avalanche photodiode (Zeiss). Photon-counting histograms (PCH) were generated using 
LSM-FCS software using a bin time of 50us or 200us for EGFP in solution and 
AKAP18γ-EGFP respectively. Both bin times are shorter than the translational diffusion 
time of their respective molecules. Fluorescence traces were integrated for 10s for each 
PCH curve. Measurements were made 10 times per location at 5 different locations 
within the cytoplasm. PCH curves were fit with a nonlinear curve fitting routine using a 
one or two component model. EGFP in solution was fit with a single component model. 
For AKAP18γ-EGFP brightness value of the first component was fixed to the measured 
brightness value of EGFP in solution.  A single-photon three-dimensional Gaussian 
model was assumed for the excitation volume. 
3.3.8. Confocal Imaging Number and Brightness Analysis 
Confocal imaging of AKAP18γ-EGFP was performed on a Zeiss LSM780 
microscope mounted on an inverted Axio Observer Z1. Excitation was achieved at 
488nm with an Argon laser at 1% power. Emission was collected through a 40X water 
objective (Zeiss C-Apochromat 1.2W Korr UV-Vis-IR) and detected by a 32-channel 
QUASAR GaAsp detector in photon counting mode. Images were collected at 512x512 
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pixels with a 3.15µs/pixel scan speed and 1.94s exposure time per frame. Images were 
saved as 8-bit and imported into SimFCS software (Laboratory for Fluorescence 
Dynamics). Detailed description of the method and analysis has been previously 
described (163). Briefly, for each image series 100 frames were analyzed. Vero cells 
expressing monomeric EGFP were imaged under the same conditions as AKAP18γ-
EGFP. The brightness of EGFP was used as the brightness of a monomer (1.29), which 
allowed for the selection of oligomeric size based upon the average brightness. 
3.3.9. Computational Modeling 
A compartmental deterministic model of scaffold oligomerization was implemented 
using the Virtual Cell modeling software. The model is composed of 17 or 20 species 
depending on whether one or multiple oligomeric states of the scaffold species are 
present in the simulation, three compartments (plasma membrane, cytosol, and 
endoplasmic reticular membrane), and 13 reactions. The reaction network can be 
considered as being composed of four general modules: 1) production and degradation of 
cAMP, 2) the dynamic interactions of regulatory subunit, catalytic subunit and cAMP in 
the cytosol, 3) the dynamics of these same proteins and cAMP scaffolded on the ER 
membrane by AKAP, and 4) phosphorylation/dephosphorylation of target protein X on 
the ER membrane. For each oligomeric state represented in the different versions of the 
model, a simulation is run to equilibrium to determine the concentration of each species. 
The equilibrium states are then used to initialize a simulation in which the amount of AC 
present on the plasma membrane is increased from 20/µm2 to 80/µm2 for a period of 
500s, simulating transient activation of the β-AR. The resulting increase in cAMP leads 
to activation of scaffolded PKA and phosphorylation of the target protein X. The ability 
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of RIIα to self-regulate via autophosphorylation has been shown previously (164). We 
hypothesized that if a single catalytic subunit were to be activated within an oligomerized 
complex of AKAP and PKA, this may subsequently lead to activation of the remaining 
population of PKA within the complex. This hypothesis was implemented via the 
following equation (eq. 1), which adjusts for the probability of all catalytic subunits 
within the oligomeric complex (n= oligomer size) becoming active following activation 
of a single catalytic subunit in the complex: 
(1) (Total AKAP bound PKA)(1-(Inactive PKA/ Total PKA) n) * n 
 This value representing the amount of catalytic subunits available to phosphorylate its 
target, X, is substituted for [E] in the Henri-Michaelis Menten irreversible reaction step 
for phosphorylation of X (eq 2). 
(2) V= ([E] * kcat * [X]) / (Km + [X]) 
A separate model was created to investigate the phosphorylation dynamic of protein X in 
the presence of all forms of the oligomer as demonstrated via FCS/N&B analysis. 
Concentrations of each oligomeric species were adjusted by tuning the forward and 
reverse rates of formation of each species. 
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3.4. RESULTS 
3.4.1. Direct cellular association of AKAP18γ  with itself. 
In order to understand the molecular architecture of the AKAP18γ signaling complex and 
determine if the AKAP can be the basis for higher order structures, we first looked to see 
if purified, recombinant AKAP18γ could isolate an AKAP18γ complex from cells.  
Lysate prepared from HEK293 cells transfected with AKAP18γ-EGFP was incubated 
with amylose beads charged with either AKAP18γ-maltose binding protein (MBP) or 
MBP alone.  As shown in Figure 3.1A, AKAP18γ-EGFP specifically associates with 
AKAP18γ-MBP, suggesting the AKAP18γ signaling complex may contain multiple 
AKAP18 scaffolds. To verify the existence of such complexes in cells, we co-expressed 
AKAP18γ-EGFP with either AKAP18γ-mCherry or mCherry alone in HEK293 cells.  
Immunoprecipitates from these cells isolated with a mCherry antibody contain 
AKAP18γ-EGFP (Figure 3.1B), while AKAP18γ-EGFP does not co-precipitate with 
mCherry control. This coprecipitation could be due to multiple binding sites on other 
common binding partners from the AKAP complex.  To determine if AKAP18γ can 
directly associate with itself, we conducted a pulldown assay using amylase beads 
charged with bacterially expressed AKAP18γ-MBP incubated with bacterially expressed 
His/S-tagged AKAP18γ.  Importantly, we detect a direct association between His/S-
tagged AKAP18γ and AKAP18γ-MBP, but not MBP alone (Figure 3.1C).  Based on 
these experiments, we conclude AKAP18γ can stably associate with itself. 
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Figure 3.1: AKAP18γ interacts with itself in cells and directly.  
A) Recombinant purified full-length maltose binding protein (MBP) tagged AKAP18γ 
precharged on amylose agarose resin was used to conduct precipitation of AKAP18γ-
EGFP from HEK cell lysates. HEK cells were transfected for over 24hours with 
AKAP18γ-EGFP before harvesting the cells for pulldown experiment. Anti-EGFP 
antibody was used for detecting protein interactions using western blot analysis. Purified 
MBP alone was used as control. B) AKAP18γ-EGFP and AKAP18γ-mCherry were co-
transfected in HEK cells for over 24 hours before harvesting the cells to prepare a cell 
lysate. Cell lysate was subjected to an immuno-precipitation experiment using antibody 
against the mCherry tag. Anti EGFP antibody was used to identify protein-protein 
interaction using western blot analysis.  C) Recombinant purified full length maltose 
binding protein (MBP) tagged AKAP18γ precharged on amylose agarose resin was used 
to conduct pulldown of recombinant purified full length His/S tagged AKAP18γ. Anti 
His antibody was used to detect the interaction using western blot analysis.  
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3.4.2. Isoform specificity and binding affinity of AKAP18γ oligomers.  
The AKAP18 gene encodes at least 4 alternatively spliced isoforms: α, β, γ and δ (131). 
The smaller isoforms, AKAP18α & AKAP18β are lipid modified in their N-terminal 
domain, directing their location to the plasma membrane (129). However, the larger 
isoforms, AKAP18γ & AKAP18δ require additional protein-protein interactions for their 
intracellular targeting (131).  We investigated whether the shorter isoforms could also 
associate with themselves or other isoforms. We first performed pulldown experiments 
using amylose beads charged with AKAP18γ-MBP on cell lysate isolated from cells 
transfected with AKAP18α-EGFP. As shown in Figure 3.2A, we did not detect the 
presence of AKAP18α with either AKAP18γ-MBP or control MBP, suggesting there is 
no cross isoform interaction. To further confirm this observation, we conducted an  
inverse experiment. Lysate collected from HEK293 cells transfected with AKAP18γ-
EGFP was incubated with S-beads charged with S-tagged AKAP18α or S-beads alone. 
As expected, we did not detect any interaction between the two isoforms (Figure 3.2B). 
To further our understanding of this interaction, we explored the detailed binding kinetics 
of the AKAP18γ interaction by surface plasmon resonance (SPR).  AKAP18γ was 
chemically conjugated on a CM5 sensor chip.  Increasing concentrations of either 
AKAP18γ (black) or AKAP18α (red) (12.5nM to 400nM) were then flowed over the 
sensor, and the binding dissociation constant was calculated.  We detect a high affinity 
interaction between AKAP18γ and itself that is best fit to a heterogeneous analyte curve, 
suggesting multiple sites of interaction displaying binding affinities of 6nM and 0.13nM 
(Figure 3.2C).  However, no significant binding between AKAP18γ and AKAP18α is  
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Figure 3.2: AKAP18γ interacts with itself with a high affinity in an isoform specific 
manner.  
A) Recombinant purified full-length maltose binding protein (MBP) tagged AKAP18γ 
precharged on amylose agarose resin was used to conduct precipitation of AKAP18α-
EGFP from HEK cell lysates. HEK cells were transfected for over 24hours with 
AKAP18α-EGFP before harvesting the cells for pulldown experiment. Anti-EGFP 
antibody was used for detecting protein interactions using western blot analysis. B) 
Recombinant purified full length His/S tagged AKAP18α precharged on Ni-agarose resin 
was used to conduct precipitation of AKAP18γ-EGFP from HEK cell lysates. HEK cells 
were transfected for over 24hours with AKAP18γ-EGFP before harvesting the cells for 
pulldown experiment. Anti-EGFP antibody was used for detecting protein interactions 
using western blot analysis. C) Surface Plasmon Resonance (SPR) experiment showing 
robust interaction between AKAP18γ ligand and AKAP18γ analyte (blue). Significant 
interaction between AKAP18α ligand and AKAP18γ analyte was not detected (red). D) 
Surface Plasmon Resonance (SPR) experiment showing lack of binding between 
AKAP18γ ligand and AKAP18α analyte (blue). AKAP18α ligand and AKAP18α analyte 
did not show interaction as well (red).  
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detected.  This was confirmed in reciprocal experiments, where we chemically 
conjugated AKAP18α to the sensor and no binding between AKAP18α and itself was 
detected (Figure 3.2D). These results support the hypothesis that AKAP18γ 
oligomerization is limited to AKAP18γ.  
3.4.3. Mapping the sites in AKAP18γ responsible for oligomerization. 
Following the detection of two sites of interaction between AKAP18γ molecules by 
our SPR analysis, we were interested in defining the sites that delineate the association. 
To address this question, we synthesized deletion constructs of the AKAP18γ-MBP.  
Amylose beads charged with these AKAP18γ deletion proteins were then incubated with 
HEK293 cell lysate expressing either the first 150 amino acids of AKAP18γ (AKAP18γ 
1-150-EGFP) or the last 182 amino acids (AKAP18γ 150-end-EGFP) (shown in Figure 
3.3A). As shown in Figure 3.3B and 3.3C, not only does full length AKAP18γ-MBP 
interact with the two halves of AKAP18γ, but both the EGFP-tagged halves associate 
with all the AKAP18γ-MBP deletion constructs.  Therefore, using this method, we were 
not able to delineate the specific amino acid binding domains on AKAP18γ that are 
responsible for this interaction. 
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Figure 3.3: Mapping for delineating specific AKAP18γ interaction domain(s).  
A) Schematic representation of EGFP tagged AKAP18γ protein constructs that were 
separately expressed in HEK cells. B) Western blot showing interaction between different 
recombinant purified MBP tagged AKAP18γ deletion mutants and AKAP18γ 1-150 
EGFP. AKAP18γ 1-150 EGFP was expressed in HEK cells for over 24 hours and cells 
were harvested to prepare cell lysates. Cell lysates were incubated with recombinant 
purified MBP tagged AKAP18γ deletion proteins precharged on amylose agarose resin. 
Antibody raised against EGFP was used to detect the interaction. C) Western blot 
showing interaction between different recombinant purified MBP tagged AKAP18γ 
deletion mutants and AKAP18γ 150-end EGFP. AKAP18γ 150-end EGFP was expressed 
in HEK cells for over 24 hours and cells were harvested to prepare cell lysates. Cell 
lysates were incubated with recombinant purified MBP tagged AKAP18γ deletion 
proteins precharged on amylose agarose resin. Antibody raised against EGFP was used to 
detect the interaction. 
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3.4.4. Mulitple oligomeric states of AKAP18γ can be detected in cells. 
The existence of two binding sites for AKAP18γ to associate with itself suggests the 
potential to form not only dimers, but higher order oligomeric structures, independent of 
the participation of other AKAP signaling complex components. This possibility was 
investigated via photon counting histogram (PCH) analysis of AKAP18γ-EGFP 
expressed in live cells. Cells expressing low yet detectable amounts of AKAP18γ-EGFP 
were selected for analysis due to the dependence of signal variance on the inverse of the 
number of particles present in the confocal volume. For each cell chosen, five regions 
were selected from within the cytoplasm for analysis. The average PCH for all 50 
measurements made within the cell is shown (Figure 4A). Fitting of the PCH with a dual-
component model in which the first component has a fixed brightness value representing 
the brightness of monomeric EGFP (data not shown) reveals the presence of AKAP18γ-
EGFP oligomers ranging in size from monomer to tetramer (Figure 4B). The average 
concentration of each oligomeric state, as measured via PCH, indicated that the 
predominant species is a dimer (45nM). The monomer and trimer are both present at 
slightly more than half the concentration of the dimer (about 25nM). Although there is 
evidence of the formation of a tetramer, brightness values representing oligomers of this 
size were seen in the fit of only 2 measurements. 
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Figure 3.4: AKAP18γ-EGFP transfected Vero cells analyzed via PCH.  
(A) Two-component fit of the average of 50 measurements in a single representative cell. 
(B) Average concentration of each oligomer. Component 1 is necessarily included in the 
fitting routine and functions to define the brightness of the monomeric state thus, fits of 
all measurements include the monomeric state. Concentrations of dimers, trimers and 
tetramers represent the average concentration of the second component detected by the 
fitting routine. 
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Further confirmation of the ability of AKAP18γ-EGFP to form oligomers in cells 
was obtained via number and brightness (N&B) analysis. This technique is similar to 
PCH analysis in its ability to detect oligomerization via analysis of signal fluctuation, yet 
it offers the advantage of spatial resolution of the oligomeric states. A series of 100 
confocal images of AKAP18γ-EGFP transfected live Vero cells (Figure 3.5A) was 
gathered. Number and brightness analysis of this series of images yields a map of both 
the intensity and brightness of all pixels within the region of interest selected for analysis 
(Figure 3.5B& C). These maps are useful for determining regions of the image in which 
protein oligomerization or aggregation is occurring.  From the brightness map it appears 
that a mix of different oligomers is present throughout the cell, and the distribution of 
each oligomeric state appears to show no significant difference in prevalence at different 
subcellular locations. Given the brightness value of EGFP measured under the same 
imaging conditions, we selected from the plot of brightness vs. intensity (Figure 3.5D) 
pixels with brightness values that are multiples the EGFP brightness and represent each 
oligomeric state (163).  The monomer (blue), dimer (green) and higher order oligomers 
(red) selected from the plot of brightness vs. intensity are displayed in the selection map 
(Figure 3.5E).  Taken together, these data demonstrate the formation of higher ordered 
AKAP18γ complexes in cells, mostly in the dimer and trimer forms. 
3.4.5. Oligomerization of AKAP18γ functions to increase target phosphorylation. 
Preliminary studies were unsuccessful in using deletion constructs to map the 
binding sites and achieve selective disruption of the oligomeric complexes.  Thus, we  
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Figure 3.5:  Brightness analysis of AKAP18γ-EGFP in Vero cells.  
(A) Confocal image of Vero cell transfected with AKAP18γ-EGFP. (B) Intensity map of 
the same image shows a region of higher intensity in the perinuclear region. (C) 
Brightness map of this image reveals an even distribution of oligomers of each size. (D) 
Brightness versus intensity plot displaying monomers, dimers, trimers, and some higher 
order oligomers. (E) Image of the cell displaying pixels with brightness corresponding to 
monomers (blue), dimers (green), trimers and higher order oligomers (red). 
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decided to test the possible functional significance of AKAP18γ oligomerization in silico. 
We created a compartmental deterministic model that simulates the dynamics of the PKA 
Regulatory (RIIα) and Catalytic subunits (Cα) in response to cAMP, both in the cytosol 
and on the Endoplasmic Reticulum (ER) membrane. We chose to model the dynamics of 
AKAP18γ at the ER due to recent work demonstrating localization of the scaffold at the 
ER in cardiac myocytes (134, 135). Included in the model is autophosphorylation of RIIα 
as this is documented as a key component for activation of Cα when complexed with RII 
(164-168). In our model, it is assumed that the probability of activation of all Cα subunits 
within an oligomer increases as the total number of activated Cα subunits increases 
(Equation 1, methods). Active Cα subunits were modeled to participate in the 
phosphorylation of a generic target protein X (X     pX) existing on the ER membrane 
(Equation 2, Methods). The time course of formation of pX is shown for separate 
simulations in which four different oligomer sizes were postulated (Figure 3.6A). Upon 
addition of adenylyl cyclase, the amount of pX increases in all cases. Removal of this 
stimulus leads to dephosphorylation of pX and return to baseline. The rate of formation 
of pX increases as the size of the oligomer increases, and the magnitude of change 
between baseline and maximum levels of pX appears to peak with the trimeric state 
(Figure 3.6B). This analysis demonstrates the possible impact of AKAP oligomerization 
on the rate of PKA substrate phosphorylation. 
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Figure 3.6: Compartmental-deterministic simulation of the effect of AKAP 
oligomerization on target phosphorylation  
(A) Time course of target protein X phosphorylation for each oligomeric state. An 
increase in cAMP concentration simulating β-AR stimulation is achieved by increasing 
the amount of active AC present on the plasma membrane from 20/um2 to 80/um2. This 
stimulation starts at 200s and lasts for 500s. (B) Change in [pX] from baseline to 
maximal phosphorylation relative to phosphorylation by the monomeric state. 
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3.5. DISCUSSION 
Significant work has demonstrated the impact of scaffolding on the organization of 
signaling proteins into discrete focal points of subcellular enzyme activity (148).  
However, information on how the molecular architecture of scaffolds influences 
phosphorylation events is currently lacking.  Here, through the use of a combination of 
protein biochemistry, state-of-the-art cellular imaging and computational modeling, we 
deciphered that the scaffolding protein AKAP18γ oligomerizes in vitro and in cells. 
Several species of the AKAP can be detected in cells, including monomers, dimers, and 
high order oligomers.  Importantly, the cellular consequence of these structures is 
increased substrate phosphorylation. These findings represent a previously unappreciated 
mechanism involved in the configuration of AKAP complexes and the regulation of 
protein phosphorylation.   
 Oligomer formation is a common process to many signal transduction networks. 
In fact, a search of the Brenda enzyme database (http://www.brenda.uni-koeln.de/) 
suggests that of the total 452 human enzymes for which the subunit composition is 
known, over 300 exist in mulitmeric states (150). Recent evidence suggests 
intracellular scaffolding proteins also oligomerize (154-156, 169). Several recent reports 
have demonstrated homo-oligomerization of AKAP5, AKAP12 and AKAP-Lbc (47, 49, 
52).  Dimer formation of these AKAPs is mediated by direct protein-protein 
interactions.  A leucine zipper motif in the N-terminus of AKAP-Lbc dictates the 
interaction while multiple domains of AKAP5 are required for dimerization (49, 52).  
AKAP18γ oligomerization is also via a direct interaction, but our mapping studies to 
define the binding motifs needed for oligomerization are inconclusive and suggest 
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multiple points of interaction. Interestingly, a crystal structure of the common central 
domain contained in the long AKAP18 isoforms (amino acids 76-292 of AKAP18γ) did 
not indicate oligomerizaiton of the AKAP (48). This structure lacks the N-terminus of 
AKAP18γ, which is predicted to exist in an unordered arrangement, according to 
FOLDindex©. Several AKAPs have a natively disorganized, unfolded configuration that 
is hypothesized to aid in the docking of a multitude of binding partners (47-49).  
However, this unstructured flexibility also significantly hinders conventional structural 
analysis. Hence, this N-terminal domain of AKAP18γ may significantly contribute to its 
oligomerization.  Other possible mechanisms include post-translational modification 
driven interactions, and coiled-coil interactions (170-172). Analysis of the AKAP18γ 
sequence using the PredictProtein web site as well as both MARCOIL and LOGICOIL 
web resources support these possibilities for AKAP18γ (Supplemental Table 3.1).  
Testing these potential mechanisms for oligomerization will help in delineating the 
means of AKAP18γ complex formation. 
 Signaling proteins utilize oligomerization to enhance their known cellular 
functions. One of the better-studied examples is the receptor tyrosine kinase (RTK).  
Dimerization of RTKs results in activation and autophosphorylation of tyrosine residues 
on the intracellular domain of the receptor (152, 173).  This step initiates the recruitment 
of other signaling proteins and propagation of signals from the receptor to intracellular 
targets. Though often thought to function in a monomeric state, a number of G-protein 
coupled receptors (GPCRs) have been shown to form both homo- and hetero-dimers, 
often resulting in enhanced activity (153, 174).  
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 The consequences of AKAP oligomerization are still unclear, but may impact 
multiple processes.  Mass spectrometry analysis of the AKAP5 complex suggests that 
upon dimerization, AKAP5 associates with four calcineurin phosphatase heterodimers, 
and two calmodulin molecules (49).  By increasing the concentration of the phosphatase 
in a localized area, it is suggested that AKAP5 can generate specific pools of second 
messenger-mediated events at the plasma membrane. How this change in stoichiometry 
affects substrate dephosphorylation or kinetics of enzyme activation has not been 
investigated.   However, another study of the native AKAP5 complex in hippocampal 
neurons suggests this increase in stoichiometry is an in vitro experiment artifact, as no 
increase in stoichiometry was detected in vivo (175).  Other processes oligomerization 
may affect include regulating the intrinsic enzymatic activity of an AKAP.  AKAP-Lbc is 
a guanine nucleotide exchange factor (GEF) for RhoA (176).  Disruption of AKAP-Lbc 
dimerization dramatically increased its GEF activity, suggesting oligomer formation acts 
to limit the basal activity of the AKAP (52).  However, AKAP18γ does not display any 
intrinsic enzymatic activity, suggesting this mechanism would not be applicable. 
 To explore the possible functional significance of AKAP18γ oligomerization, we 
created a computational model of PKA scaffolding. Significant work has demonstrated 
that release of active C subunit from the PKA holoenzyme requires not only cAMP 
binding to the RII subunit, but also autophosphorylation of RII (164-168). This leads us 
to hypothesize that in the context of an AKAP18γ oligomer, release of a single Cα 
subunit can potentiate the release of additional Cα via phosphorylation of RIIα present in 
the oligomer. In the monomeric state, a single Cα can stimulate release of only one extra 
Cα subunit, but, in an oligomeric state such as a tetramer, release of up to seven 
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additional Cα subunits is possible. This feed-forward loop ultimately increases substrate 
phosphorylation due to the increased probability of phosphorylation resulting from 
increased Cα release (Figure 3.7). This is simulated by defining activation of PKA in the 
AKAP18α complex as a probability function in which the chance of activating all Cα 
subunits increases as the number of active Cα subunits within the complex increases (Eq. 
1). The model demonstrates that oligomerization of AKAP18γ does indeed enhance 
target phosphorylation, increasing the magnitude of change in phosphorylation of 
substrate X (pX) with oligomer size up to a trimer. This pattern correlates well with our 
PCH and N&B data, suggesting that the predominant AKAP18γ species is a dimer, with 
less monomer and trimer, and relatively no tetramer. 
In conclusion, we have discovered an additional component of the AKAP18γ 
signaling complex and demonstrated oligomerizaiton of the AKAP impacts 
phosphorylation of PKA substrates.  As several PKA targets of AKAP18γ have been 
identified, including PDE4D, the PP1 inhibitor I-1 and the cardiac calcium regulatory 
protein phospholamban, AKAP18γ oligomerization will likely effect phosphorylation of 
these endogenous substrates.   
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3.6. SUPPLEMENTARY FIGURES AND TABLE 
 
Supplementary Figure 3.1: Binding of R2 and AKAP18 isoforms 
R2 does not show significant difference in binding to AKAP18α (non-ologimerizing 
AKAP18) and AKAP18γ (oligomerizing AKAP18). 5uM purified RII 1-47 GST was 
incubated with 1uM each of either His/S-AKAP18α or His/S-AKAP18γ to conduct a 
pulldown experiment. The proteins were incubated together for a few hours in solution 
followed by addition of 20uL S-agarose beads and the pulldown was carried on for a few 
more hours. The precipitates were spun-down and thoroughly washed 3X using His 
protein purification buffer having protease inhibitors, followed by a high-salt wash 
(600mM NaCl in His purification buffer). Lamelli buffer was added to the precipitates 
and SDS-PAGE was performed followed by coomassie staining. 
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Supplementary Table 3.1:  
Table showing the list of possible post-translational modifications AKAP18γ may 
undergo as a possible mechanism for oligomerization. Data extracted from 
predictprotein.org.
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4. CONCLUSIONS AND FUTURE DIRECTIONS 
 
The focal point of my thesis has been establishing AKAP18γ as a novel AKAP 
that regulates I-1 phosphorylation by localizing it to the AKAP18γ complex and 
oligomerizes to enhance substrate phosphorylation. The novelty of my thesis work is the 
discovery that AKAP18γ is involved in direct interaction with I-1 and importantly, 
enhances its phosphorylation by PKA. AKAP18γ can concomitantly interact with PKA, 
PP1 and I-1 making an AKAP18γ complex and I found that PP1 can be inhibited by this 
complex in a PKA activation dependent manner. Moreover, the thesis work presented 
here provides a direct experimental evidence of enhancement in I-1 phosphorylation 
when bound to AKAP18γ. I also show that AKAP18γ oligomerizes in vitro and in cells 
and computational modeling shows that based on this oligomerization more PKA 
catalytic subunits can be released from the complex which improves phosphorylation of 
generic substrate in a specific cellular compartment. 
Another unique facet of AKAP18γ complex is that PP1 does not directly interact 
with this AKAP. Immuno-precipitation and direct binding experiments confirm that 
AKAP18γ is able to pulldown PP1 from rat heart extract but purified PP1 does not 
directly interact with purified AKAP18γ. Even though, it has been previously established 
that PP1 and I-1 can directly interact (87); in my experiments, purified I-1 could not 
mediate AKAP18γ and PP1 interaction suggesting that there is another PP1 binding 
partner that localizes PP1 to this complex. A glycogen binding scaffolding protein GM 
has been reported to be present in the SR membrane in order to localize PP1 required for 
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de-phosphorylation of PLN. Moreover, the intra-membrane domain of PLN directly 
interacts with intra-membrane domain of GM (177). Based on this evidence, we had 
proposed that GM might be the connecting link between AKAP18γ and PP1 interaction. 
Using SPR to test protein-protein interaction, I found that GM 1-240 GST does not 
interact with AKAP18γ. On the other hand, SPR experiments also confirmed that the 
same domain of GM, GM 1-240 GST could interact with PLN with high affinity [Figure 
4.1]. Based on these results, other domains of the GM protein should be tested for 
interaction with AKAP18γ. Also, mass spectrometric analysis of AKAP18γ 
immunoprecipitates from human heart homogenate or mouse heart homogenate should be 
conducted to identify the linking protein that mediates AKAP18γ and PP1 interaction. 
The key finding that AKAP18γ can bind to I-1 opens up a new field of AKAP 
mediated regulation of this PP1 inhibitor which was previously unknown.  PP1 is a 
highly regulated protein and it has been described in Chapter 1 how multiple subsets of 
PP1 binding proteins participate and contribute to PP1 regulation. The discovery that an 
AKAP can bind the PP1 endogenous inhibitor adds to our understanding of yet another 
layer of regulation. In an effort towards understanding the molecular basis of this 
interaction, I conducted mapping experiments to delineate a binding domain of 
interaction between AKAP18γ and I-1. For this, I synthesized deletion constructs of GFP 
tagged AKAP18γ that can be transfected into mammalian cell for expression followed by 
pulldown using purified recombinant I-1 GST. These experiments showed that AKAP18γ 
bound I-1 GST at multiple sites as all deletion constructs of AKAP18γ-GFP were able to 
bind to I-1 GST. I also attempted mapping the AKAP18γ binding site by expressing 
recombinant His tagged deletion constructs of AKAP18γ that can be purified from  
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Figure 4.1: GM 1-240 GST interacts with PLN with high affinity.  
Kinetics data from SPR experiement showing association and disassociation curves for 
GM 1-240 GST (analyte) binding to PLN (ligand). Increasing concentrations of GM1-240 
GST was used for kinetics analysis (25-400nM). The SPR program determined a KD of 
9.71 E -09.   
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transformed E. coli. The purified deletion constructs of AKAP18γ when used for a pull-
down experiment with I-1 GST yielded an inconclusive answer like the previous result 
[data not shown].  A plausible reason for the failure of this mapping approach could be 
the highly disordered structure of C-and N-terminus of AKAP18γ and native 
conformation of I-1 protein. Following these attempts at mapping the AKAP18γ domain 
required for I-1 interaction, an SPR study was conducted to understand the molecular 
determinants of this interaction. SPR kinetics data revealed that the two proteins 
interacted with a high affinity and kinetics curves generated by this experiment best fit a 
two site interaction model of protein-protein interaction [Figure 4.2] suggesting there are 
two AKAP18γ domains that interact with I-1. In an inverse experiment, biotinylated I-1 
peptides (1-40, 41-80, 81-120 and 121-end) were used for testing interaction with 
AKAP18γ. To our surprise, I-1 C terminus half constituting peptides (81-120 and 121-
end) did not show any binding to AKAP18γ whereas, both the N-terminus peptides (1-40 
and 41-80) showed tight binding to AKAP18γ [Figure 4.3]. These results are suggestive 
of the fact that the PP1 inhibiting domain of I-1 is also involved in AKAP18γ interaction. 
Future efforts focusing on delineating the I-1 motifs required for AKAP18γ and I-1 
interaction will be useful in understanding how these two proteins together regulate PP1. 
Peptide micro-array approach can be used for deciphering the motif(s) involved in 
AKAP18γ and I-1 interaction. 
AKAP18γ had been found to be expressed in multiple tissues and its importance 
in cardiac calcium regulation is indirectly established. The already existing evidence of 
AKAP18δ being localized to SR membrane by virtue of protein-protein interaction with 
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Figure 4.2: I-1 GST interacts with AKAP18γ with high affinity.                                          
Kinetics data from SPR experiement showing association and disassociation curves for I-
1 GST (analyte) binding to AKAP18γ (ligand). Increasing concentrations of I-1GST was 
used for kinetics analysis (12.5-200nM). The SPR program determined a two-site 
interaction model for I-1GST and AKAP18γ. The two KDs as calculated by the SPR 
program are: KD1= 8.86 E-07 and KD2= 6.51 E-07.   
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Figure 4.3: I-1 peptides interact with AKAP18γ with high affinity.  
Kinetics data from SPR experiment showing association and disassociation curves for 
biotinylayed I-1 peptides (ligand) binding to AKAP18γ (analyte). Increasing 
concentrations of AKAP18γ was used for kinetics analysis (12.5-200nM) for each 
analysis. The KD for I-1 1-40 peptide (A) vs AKAP18γ determined by the SPR program 
was 1.07 E-08 and that for I-1 41-80 peptide (B) vs AKAP18γ was 2.39 E-09.  
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PLN supports this hypothesis. In this specific study, Lygren et al. had used rat cardiac 
myocytes as their model. Competing AKAP18δ interaction with PLN using peptides 
resulted in attenuation of PKA mediated phoshorylation of PLN in cardiac myocytes 
confirming the importance of AKAP18δ in rat cardiac myocytes (134). A recent 
publication dedicated to studying AKAP18 isoform distribution across species found that 
AKAP18γ is the dominant cardiac cytoplasmic isoform in humans while AKAP18δ 
serves the same role in rat cardiac myocytes. This group also confirmed that AKAP18γ 
and AKAP18δ are localized to cardiac SR in mice which expresses both the isoforms  
(135). Moreover, SPR experiment in our lab revealed that human AKAP18γ interacts 
with human PLN with a high affinity (KD in low nano-molar range). It is also known that 
in canine cardiac myocytes, about 78% of total I-1 is concentrated at the SR for PP1 
regulation (121). Put together, data from my research and others suggests that an 
AKAP18γ complex consisting of PKA, PP1 and I-1 may be localized in different pockets 
of the cell for specific PP1 regulation. As mentioned earlier, a well-characterized 
AKAP18δ target is PLN (in rats) and hence we hypothesize that in humans and in mice, 
AKAP18γ complex might exist at cardiac SR for regulation of PLN phosphorylation 
status in two ways. First, this complex directly mediates PLN phosphorylation. Second, 
AKAP18γ prevents PLN de-phosphorylation by inhibiting PP1. Moreover PLN, 
AKAP18γ, PP1 and I-1 are also expressed in skeletal muscle, brain and liver tissues as 
well, which suggests that this complex may be assembled in other tissue types. These 
evidence based predictions need to be confirmed as a next step study of this thesis work. 
Another important discovery by our laboratory was AKAP18γ association with 
PKC isoforms (178).  PKC mediated phosphorylation of I-1 prevents I-1 mediated PP1 
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inhibition (115). Binding of PKC to this complex indicates existence of dual regulatory 
system for I-1. As shown in figure 4.4, PKA mediated phosphorylation of I-1 potentiates 
it for PP1 inhibition, while PKC mediated phosphorylation disables I-1 from inhibiting 
PP1. My work provides evidence for enhanced PKA mediated phosphorylation of 
AKAP18γ bound I-1 upon beta-adrenergic activation of cells. We believe AKAP18γ will 
also mediate the PKC-dependent phosphorylation of I-1 as well.  Future work focused on 
exploring the physiological conditions that augment PKA and PKC mediated 
phosphorylation of AKAP18γ bound I-1 will help understand the importance of 
AKAP18γ in mediating these phosphorylations ultimately for PP1 regulation. 
Experimental evidence from our laboratory shows that AKAP18γ interacts not 
only with PKA, PP1, I-1 and PKC, but also with AC5 and PDE4D3. Even though, PLN is 
a substrate of AKAP18γ/δ complex and helps localize AKAP18γ/δ to the SR, one 
possibility that needs to be tested is if AKAP18γ complex is organized to regulate I-1 in 
other cell compartments. Furthermore, based on this data, it appears that AKAP18γ 
provides a scaffolding surface for activation and de-activation of PKA itself. It is known 
that PDE4D3 activation is mediated by PKA phosphorylation at its N-terminus and in the 
UCR1 (Upstream Conserved Region 1) (179). PKA mediated phosphorylation of AC5 
deactivates this enzyme (180). This suggests that upon activation PKA phosphorylates 
PDE4D3 and AC5 to promote its own de-activation. It remains to be tested if this 
hypothesis is true and if these two PKA mediated phosphorylations of PDE4D and AC5 
affects I-1 phosphorylation status.  
Over the course of my work and others in the laboratory, we have accumulated 
evidence to suggest that AKAP18γ belongs to the family of AKAPs that form  
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Figure 4.4: Proposed AKAP18γ  mediated regulation of I-1.  
 
Shown in the diagram is the proposed model of I-1 regulation by tethered PKA and PKC 
based on cellular environment. PKC gets activated when there is an increase in Calcium 
(Ca2+) in the cell. Calcium gradient has been represented by the shaded blue heavy arrow. 
Darker shade reflects increase in calcium concentration. Light blue arrows show PKC-
mediated phosphorylaton of I-1 and consequently no PP1 inhibition. PKA activation 
occurs due to increase in cAMP in the cell. cAMP gradient has been represented by a 
shaded red to yellow heavy arrow. Red shade indicates high cAMP concentration. Red 
arrows show PKA-mediated Phosphorylation of I-1, which inhibits PP1 activity.
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multi-molecular complexes. Our lab has established that AKAP18γ interacts with PKC, 
PDE4D, AC5, PP1 and I-1. My thesis work showed that AKAP18γ is required for this 
complex formation as in the absence of AKAP18γ, PP1 and I-1 were unable to interact 
with PKA. My work also provides evidence for the constitutive presence of PP1, I-1 and 
PKA bound to AKAP18γ in cell extract. Future work involving understanding the 
conditions in which different components of the AKAP18γ are assembled and 
disassembled will be helpful in understanding the dynamics of the AKAP18γ complex. 
More studies focused towards identifying separate pools of AKAP18γ complexes 
involving specific protein binding partners will also be useful in understanding whether 
the AKAP18γ complex can bind all the identified binding partners at the same time or 
AKAP18γ regulates the activity of its binding partners in discrete AKAP18γ complexes. 
Another finding of my thesis project is AKAP18γ oligomerization. I conceived 
the idea based on the premise that AKAP18γ would require a large binding surface for 
the reported protein associations to occur concurrently (described above). Binding 
affinity data available in our laboratory reports high affinity interaction between 
AKAP18γ and I-1, AC5, PLN and PDE4D3 separately, with low disassociation rates for 
these interactions. This data is suggestive of stable interaction of these proteins with 
AKAP18γ. Towards testing the AKAP18γ oligomerization hypothesis, with the help of 
pulldown experiments using over-expression systems, I have been able to show that 
AKAP18γ can bind to itself. Moreover, to further the understanding, I collaborated with 
my labmates, Dr. Andrew Le and Marc Rigatti, to understand the molecular details of this 
process, as described in chapter 3. Our results suggest that oligomerization of AKAP18γ 
would cause recruitment of multiple PKA holo-enzymes, and under activated conditions 
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multiple PKA catalytic subunits would be released because of efficient PKA-regulatory 
subunit auto-phosphorylation. Multiple PKA catalytic subunits cause improved substrate 
phosphorylation. Future work will involve understanding the molecular basis of 
AKAP18γ interaction with itself to develop reagents that will disrupt AKAP18γ 
oligomeriation in cells. It will be interesting to find out if disruption of AKAP18γ 
oligomerization affects PKA mediated phosphorylation of PKA substrates associated 
with AKAP18γ complex. 
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5. IMPACT OF THESIS WORK 
  The key discovery that AKAP18γ can directly regulate endogenous PP1 
inhibitor protein I-1, was unknown before this thesis work. This study puts forth a new 
mechanism in which the endogenous PP1 inhibitor I-1 is localized and primed for PP1 
inhibition as a part of a feed forward mechanism that promotes PKA signal 
propagation. Moreover, AKAP18γ was found to oligomerize which is indicative of a 
mechanism to enhance PKA mediated phosphorylation of multiple substrates by this 
AKAP. AKAP18γ can interact with important PKA substrates PLN, PDE4D and AC5. 
Together these discoveries point to a multi-molecular complex tethered by an AKAP18γ 
oligomer localized to SR for regulation of cardiac calcium cycling via PLN 
phosphorylation control. 
  PP1 is involved in the regulation of a plethora of cellular processes. A complete 
understanding of pathways and cellular domain specific PP1 regulation will contribute 
towards complete understanding of how cellular signaling pathways function. 
Moreover, detailed understanding of PP1 regulation in the context of particular 
substrates will greatly help in the development of next generation drugs that focus on 
treating defective pathways and proteins specifically. The importance of pathway 
specific treatment is currently being realized in the treatment of cardiac disorders 
[Figure 5.1]. 
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Figure 5.1: AKAP18 complex based on thesis and work by other labs.  
AKAP18γ oligomerizes making all ranges of structures between monomers and tetramers 
(shown as AKAP18γ/δ x 1-4). AKAP18γ directly interacts with its two substrates at the 
SR, PLN and I-1. Phosphorylation of PLN augments cardiac calcium cycling. 
Concomitant phosphorylation of I-1 enhances cardiac cycling by inhibiting PP1 and 
preserving PLN phosphorylation.  
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